Novel-N-(bicyclic heterocyclyl)-4-piperidinamines

ABSTRACT

Novel N-(bicyclic heterocyclyl)-4-piperidinamines having antihistaminic and serotonin-antagonistic properties which are useful in the treatment of allergic diseases.

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a division of application Ser. No. 487,774, filed Apr. 22, 1983,now U.S. Pat. No. 4,556,660, which in turn is a continuation-in-part ofapplication Ser. No. 397,626, filed July 12, 1982, now abandoned.

BACKGROUND OF THE INVENTION

In U.S. Pat. No. 4,219,559 there are described a number ofN-heterocyclyl-4-piperidinamines having the formula ##STR1## whichcompounds are useful as antihistaminic agents.

The compounds of the present invention differ from the prior artcompounds essentially by the nature of the 1-piperidinyl substituent andby the fact that the compounds of the present invention are not onlypotent histamine-antagonists but also potent serotonin-antagonists.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

This invention is concerned with novel N-heterocyclyl-4-piperidinamineswhich may structurally be represented by the formula ##STR2## thepharmaceutically acceptable acid addition salts and the stereochemicallyisomeric forms thereof, wherein:

A is a bivalent radical having the formula

--CH═CH--CH═CH--(a),

--N═CH--CH═CH--(b),

--CH═N--CH═CH--(c),

--CH═CH--N═CH--(d), or

--CH═CH--CH═N--(e),

wherein one or two hydrogen atoms in said radicals (a)-(e) may, eachindependently from each other, be replaced by halo, lower alkyl, loweralkyloxy, trifluoromethyl or hydroxy;

R is a member selected from the group consisting of hydrogen and loweralkyl;

R¹ is a member selected from the group consisting of hydrogen, alkyl,cycloalkyl, Ar¹ and lower alkyl substituted with one or two Ar¹radicals;

R² is a member selected from the group consisting of hydrogen, loweralkyl, cycloalkyl, (lower alkyl)--CO-- and Ar² -lower alkyl;

L is a member selected from the group consisting of

a radical of formula ##STR3## a radical of formula

    Het--C.sub.s H.sub.2s --Y--Alk--(g);

and a radical of formula ##STR4## wherein n is 0 or the integer 1 or 2;

s is 0 or an integer of from 1 to 6 inclusive;

Alk is lower alkanediyl;

Y is O, S, NR³ or a direct bond;

X is O, S, CH--NO₂ or NR⁴ ;

Z is O, S, NR⁵ or a direct bond; and

Het is an optionally substituted 6-membered heterocyclic ring having atleast one nitrogen atom and being optionally condensed with anoptionally substituted benzene ring, said Het being connected to C_(s)H_(2s) on a carbon atom;

said R³ being hydrogen, lower alkyl, (Ar²)lower alkyl, 2-loweralkyloxy-1,2-dioxoethyl or a radical of formula --C(═X)--R⁶, R⁶ beinghydrogen, lower alkyl, Ar², Ar² -lower alkyl, lower alkyloxy, Ar² -loweralkyloxy, mono-or di(lower alkyl)amino, Ar² -lower alkylamino or Ar²-lower alkyl(lower alkyl)amino;

said R⁴ being hydrogen, lower alkyl, cyano, nitro, Ar² -sulfonyl, loweralkylsulfonyl, lower alkylcarbonyl or Ar² -carbonyl; and

said R⁵ being hydrogen or lower alkyl;

provided that Het is other than pyridinyl or mono- or di(loweralkyloxy)pyridinyl where L is a radical (g) wherein Y is NR³ or where Lis a radical (h) wherein X is O and Z is NR⁵ or a direct bond;

wherein Ar¹ is a member selected from the group consisting of phenyl,being optionally substituted with up to three substituents eachindependently selected from the group consisting of halo, hydroxy,nitro, cyano, trifluoromethyl, lower alkyl, lower alkyloxy, loweralkylthio, mercapto, amino, mono- and di(lower alkyl)amino, carboxyl,lower alkyloxycarbonyl and (lower alkyl)--CO--; thienyl; halothienyl;furanyl; lower alkyl substituted furanyl; pyridinyl; pyrazinyl;thiazolyl and imidazolyl optionally substituted by lower alkyl; andwherein Ar² is a member selected from the group consisting of phenylbeing optionally substituted with up to three substituents eachindependently selected from the group consisting of halo, hydroxy,nitro, cyano, trifluoromethyl, lower alkyl, lower alkyloxy, loweralkylthio, mercapto, amino, mono- and di(lower alkyl)amino, carboxyl,lower alkyloxycarbonyl and (lower alkyl)--CO.

As used in the foregoing definitions the term halo is generic to fluoro,chloro, bromo and iodo; the term "lower alkyl" is meant to includestraight and branch chained saturated hydrocarbon radicals having from 1to 6 carbon atoms such as, for example, methyl, ethyl, 1-methylethyl,1,1-dimethylethyl, propyl, -methylpropyl, butyl, pentyl, hexyl and thelike; "alkyl" is meant to include lower alkyl radicals, as definedhereinabove, and the higher homologs thereof having from 7 to 10 carbonatoms; the term "cycloalkyl" is generic to cyclopropyl, cyclobutyl,cyclopentyl and cyclohexyl; and "lower alkanediyl" is meant to includebivalent straight or branch chained alkanediyl radicals having from 1 to6 carbon atoms.

The compounds of formula (I) wherein Het is a heterocycle which issubstituted with a hydroxy radical may contain in their structure aketo-enol system or a vinylog system thereof and consequently thesecompounds may be present in their keto form as well as their enol form.

Preferred compounds within the invention are those wherein Het is amember selected from the group consisting of a pyridinyl radical whichis optionally substituted with one or two substituents eachindependently selected from the group consisting of halo, amino, nitro,cyano, aminocarbonyl, lower alkyl, lower alkyloxy, lower alkylthio,lower alkyloxycarbonyl, hydroxy, lower alkylcarbonyloxy, Ar² -loweralkyl and carboxyl; a pyridinyloxide radical optionally substituted withnitro, a quinolinyl radical which is optionally substituted with a loweralkyl radical; a pyrimidinyl radical which is optionally substitutedwith one or two substituents each independently selected from the groupconsisting of halo, amino, hydroxy, lower alkyl, lower alkyloxy, loweralkylthio and (Ar²)-lower alkyl; a quinazolinyl radical which isoptionally substituted with a hydroxy radical or a lower alkyl radical;a pyridazinyl radical which is optionally substituted with a lower alkylradical or a halo radical; a quinoxalinyl radical which is optionallysubstituted with a lower alkyl radical; a pyrazinyl radical which isoptionally substituted with a halo radical, an amino radical or a loweralkyl radical; a phthalazinyl radical which is optionally substituted bya halo radical; and a 5,6-dihydro-4H-1,3-thiazin-2-yl radical.

Particularly preferred compounds are those wherein L is a radical (g) or(h) wherein Het is as described hereinabove for the preferred compounds.

More particularly preferred compounds are those wherein L is a radical(g) or (h) wherein Het is other than an optionally substituted pyridinylradical.

The most preferred compounds are selected from the grocp consisting of1-[(4-fluorophenyl)methyl]-N-[1-[2-[(2-pyrimidinyl)-amino]ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine and the pharmaceuticallyacceptable acid-addition salts thereof.

The compounds of formula (I) can generally be prepared by reacting anintermediate of formula (II) with a piperidine of formula (III)following art-known alkylating procedures. ##STR5## In (II) and (III)Het, R, R¹, R² and A are as previously described and Q₁ and Q₂ areselected so that in combination with Het a bivalent radical of formula(f), (g) or (h) is formed during the alkylation reaction, said (f), (g)and (h) having the previously described meaning.

For example, the compounds of formula (I) can generally be prepared byN-alkylating a piperidine of formula (III) wherein Q₂ is hydrogen, saidpiperidine being represented by the formula (III-a), with a reagent offormula (II) having the general formula L-W, (II-a). ##STR6## In (II-a)W represents an appropriate reactive leaving group such as, for example,halo, e.g., chloro, bromo or iodo, or a sulfonyloxy group, e.g.methylsulfonyloxy or 4-methylphenylsulfonyloxy.

Additionally, the compounds of formula (I) wherein L is a radical offormula (f), a radical of formula (g) wherein Y is other than a directbond, Y', or a radical of formula (h) wherein Z is other than a directbond, Z', said compounds being represented by the formulae (I-a-1),respectively (I-a-2) and (I-a-3), can be prepared by alkylating apiperidine of formula (III-b) with a reagent of formula (II-b). ##STR7##

In (III-b) Q_(2a) is a radical of formula ##STR8## respectively aradical of formula HY'-Alk- or ##STR9## In (II-b) W' has the previouslydefined meaning of W and, where s is 0, it may also represent a loweralkyloxy or lower alkylthio group.

The compounds of formula (I-a-2) may also be prepared by alkylating apiperidine of formula (III) wherein Q₂ is a radical of formula -Alk-W,said piperidine being represented by the formula (III-c), with a reagentof formula (II) wherein Q₁ is a radical of formula --C_(s) H_(2s) --Y'H,said reagent being represented by the formula (II-c). ##STR10##

The compounds of formula (I) wherein L is a radical of formulaHet--C_(s) H_(2s) --Z--C(═X)--Y'--Alk, said compounds being representedby the formula (I-a-4), may also be prepared by N-alkylating apiperidine of formula (III--c) with a reagent of formula (II) wherein Q₂is a radical of formula --C_(s) H_(2s) --Z--C(═X)--Y'H, said reagentbeing represented by the formula (II-d). ##STR11##

The alkylation reactions are conveniently conducted in an inert organicsolvent such as, for example, an aromatic hydrocarbon, e.g., benzene,methylbenzene, dimethylbenzene, and the like; a lower alkanol, e.g.,methanol, ethanol, 1-butanol and the like; a ketone, e.g., 2-propanone,4-methyl-2-pentanone and the like; and ether, e.g., 1,4-dioxane,1,1'-oxybisethane, tetrahydrofuran and the like; N,N-dimethylformamide(DMF); N,N dimethylacetamide (DMA); nitrobenzene;1-methyl-2-pyrrolidinone; and the like. The addition of an appropriatebase such as, for example, an alkali metal carbonate or hydrogencarbonate, sodium hydride or an organic base such as, for example,N,N-diethylethanamine or N-(1-methylethyl)-2-propanamine may be utilizedto pick up the acid which is liberated during the course of thereaction. In some circumstances the addition of an iodide salt,preferably an alkali metal iodide, is appropriate. Somewhat elevatedtemperatures may enhance the rate of the reaction.

The compounds of formula (I) wherein L is a radical of formula (h)wherein Z is Z', Y is NH and X is O or S, said X being represented by X'and said compounds by the formula (I-b-1), can generally be prepared byreacting an isocyanate or isothiocyanate of formula (V) with a reagentof formula (IV). ##STR12##

The compounds of formula (I) wherein L is a radical of formula (h)wherein Z is NH, Y is Y' and X is X', said compounds being representedby the formula (I-b-2), can be prepared by reacting an isocyanate orisothiocyanate of formula (VI) with a piperidine of formula (VII).##STR13##

The reaction of (IV) with (V) and (VI) with (VII) is generally conductedin a suitable reaction-inert solvent such as, for example, an ether,e.g., tetrahydrofuran and the like. Elevated temperatures may besuitable to enhance the rate of the reaction.

The compounds of formula (I) wherein L is a radical of formula (h)wherein Z is a direct bond and X is X', said compounds being representedby the formula (I-c), may be prepared by reacting a piperidine offormula (VII) with a reagent of formula (VIII). ##STR14##

The reaction of (VII) and (VIII) may generally be conducted followingart-known esterification- or amidation reaction-procedures, e.g., byconverting the carboxylic acid function into a reactive derivative,e.g., an anhydride or a carboxylic halide function, and subsequentlyreacting this reactive derivative with a reagent of formula (VII). Asuitable reaction is, for example, by stirring (VIII) with2-quinolinecarboxylic acid in a suitable solvent in the presence ofN,N-diethylethanamine and conver:ing the intermediately formed reactiveproduct into the desired ester or amide.

The compounds of formula (I) wherein L is a radical of formula (g)wherein Y is a direct bond and s is 0, said compounds being representedby the formula (I-d), may also be prepared by reacting an alkenylene offormula (IX) with a piperidine of formula (III-a) by stirring and, ifdesired, heating the reactants together. ##STR15##

The compounds of formula (I) can also be prepared by thecyclodesulfurization reaction of an appropriate thiourea derivative ofthe formula ##STR16## Said cyclodesulfurization reaction may be carriedout by the reaction of (X) with an appropriate alkyl halide, preferablyiodomethane in an appropriate reaction-inert organic solvent, e.g., alower alkanol such as methanol, ethanol, 2-propanol and the like.Otherwise, the cyclodesulfurization reaction may be carried out by thereaction of (X) with an appropriate metal oxide or salt in anappropriate solvent according to art-known procedures.

For example, the compounds of formula (I) can easily be prepared by thereaction of (IV) with an appropriate Hg(II) or Pb(II) oxide or salt,such as, for example HgO, HgCl₂, Hg(OAc)₂, PbO or Pb(OAc)₂. In certaininstances it may be appropriate to supplement the reaction mixture witha small amount of sulfur. Even so methanediimines, especiallyN,N'-methanetetraylbiscyclohexanamine] may be used as cyclodesulfurizingagents. Suitable reaction-inert organic solvents that may advantageouslybe employed include lower alkanols, e.g., methanol, ethanol, 2-propanoland the like; halogenated hydrocarbons, e.g., dichloromethane andtrichloromethane; ethers, e.g. tetrahydrofuran, 2,2'-oxybispropane andthe like; and mixtures of such solvents.

The compounds of formula (I) can also be converted into each otherfollowing art-known procedures of functional grouptransformation. Someexamples will be cited hereinafter.

The compounds of formula (I) having a nitro substituent can be convertedinto their corresponding amines by stirring and, if desired, heating thestarting nitro-compounds in a hydrogen-containing medium in the presenceof a suitable amount of an appropriate catalyst such as, for example,platinum-on-charcoal, palladium-on-charcoal, Raney-nickel and the likecatalysts. Suitable solvents are, for example, alcohols, e.g., methanol,ethanol and the like.

Halo atoms substituted on aryl groups may be replaced by hydrogenfollowing art-known hydrogenolysis procedures, i.e. by stirring and, ifdesired, heating the starting compounds in a suitable solvent underhydrogen atmosphere in the presence of an appropriate catalyst, e.g.,palladium-on-charcoal and the like catalysts. Said halo atoms may alsobe replaced by a lower alkyloxy or a lower alkylthio substituent byreacting the starting halo-compound with an appropriate alcohol orthioalcohol or, preferably, an alkali- or earth alkaline metal salt oran appropriate alcohol or thioalcohol in a suitable solvent.

The compounds of formula (I) wherein L is a radical (g) wherein Y is NHcan be converted into a compound of formula (I) wherein L is a radical(g) wherein Y is N--CO(lower alkyl) or N--CO(Ar²) by reacting thestarting amine with an appropriate carboxylic acid or a derivativethereof such as, for example, an acid halide, an acid anhydride and thelike.

In all of the foregoing and in the following preparations, the reactionproducts may be isolated from the reaction mixture and, if necessary,further purified according to methodologies generally known in the art.

The compounds of formula (I) have basic properties and, consequently,they may be converted to their therapeutically active non-toxic acidaddition salt forms by treatment with appropriate acids, such as, forexample, inorganic acids, such as hydrohalic acid, e.g. hydrochloric,hydrobromic and the like, and sulfuric acid, nitric acid, phosphoricacid and the like; or organic acids, such as, for example, acetic,propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic,propanedioic, butanedioic, (Z)-2-dioic, (E)-2-butenedioic,2-hydroxybutanedioic, 2,3-dihydroxybutanedioic,2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic,benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic,2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids.Conversely the salt form can be converted by treatment with alkali intothe free base form.

A number of intermediates and starting materials in the foregoingpreparations are known compounds which may be prepared according toart-known methodologies of preparing said or similar compounds and someintermediates are new. A number of such preparation methods will bedescribed hereinafter in more detail.

The intermediates of formula (III-a) can conveniently be preparedstarting from a thiourea derivative of formula ##STR17## wherein P is anappropriate protective group such as, for example, loweralkyloxycarbonyl, Ar² --CH₂ --O--CO--, Ar² --CH₂ --O and the like, by acyclodesulfurization reaction following the same procedure as describedhereinabove for the preparation of (I) starting from (X) and,subsequently eliminating the protective group P in the thus obtainedintermediate of formula ##STR18##

The elimination of the protective group P in (XII) may generally becarried out following art-known procedures such as, for example, byhydrolysis in alkaline or acidic aqueous medium.

The intermediates of formula (III-b) and (III-c) may be derived from thecorresponding intermediates of formula (III-a) by reacting the latterwith a suitable reagent following art-known N-alkylating procedures.

For example, intermediates of formula (III-b) wherein Q_(2a) representsa radical of formula H₂ N--CH₂ --Alk'--, (III-b-1), can also be preparedby reacting an intermediate of formula (III-a) with a nitrile of formula(XIII) following art-known N-alkylating procedures and subsequentlyconverting the thus obtained nitrile (XIV) into the corresponding amine(III-b-1) following art-known nitrile to amine reducing procedures,e.g., by catalytically hydrogenating procedures and the like. ##STR19##In (XIII), (XIV) and (III-b-1) Alk' has the same meaning as Alk providedthat one methylene function is missing.

The intermediates of formula (III-b) wherein Q_(2a) represents a radicalof formula HY'--CH₂ --CH₂ --, (III-b-2), may also be prepared by thereaction of (III-a) with a reagent of formula (XV) by stirring and, ifdesired, heating the reactants together in a suitable solvent. ##STR20##The intermediatas of formula (III-b) wherein Q_(2a) is a radical offormula HX-Alk-, (III-d), may be converted into an intermediate offormula (III-c) by converting the function XH into an appropriateleaving group, e.g., where X is O, by converting a hydroxy function intoa chloro atom, with thionyl chloride, phosphoryl chloride and the like.##STR21##

The intermediates of formula (III-b-1) may also be derived from anappropriate corresponding carbonyl-oxidated form by reacting saidcarbonyl-oxidated form with hydroxylamine and reducing the thus obtainedoxime following art-known methods, e.g., catalytic hydrogenation and thelike reducing methods.

During one of the reactions the intermediates wherein R¹ and/or R²and/or R³ and/or R⁴ is hydrogen may be converted into the correspondingintermediates wherein R¹ and/or R² and/or R³ and/or R⁴ is other thanhydrogen following art-known N-alkylating, N-acylating or reductiveN-alkylating procedures.

The intermediates of formula (XI) may be prepared by reacting apiperidine of formula (XVI-a) or (XVI-b) with an aromatic reagent offormula (XVII-a) or (XVII-b). ##STR22##

The intermediates of formulae (III-b) and (XIV) wherein A is a radicalhaving the formula (c), (d) or (e), (III-b-2), respectively (XIV-a) arenew and as intermediates as well as antihistaminic agents andserotonin-antagonists these 3H-imidazo[4,5-c]pyridin-2-amines,1H-imidazo[4,5-b]pyridin-2-amines and 1H-imidazo[4,5-c]-pyridin-2-aminesof formulae (III-b) and (XIV) constitute an additional purpose of thepresent invention.

The compounds of formula (I) and the intermediates of formula (III-b-2)and (XIV-a) wherein A is a radical of formula --CH═N--CH═CH--,--CH═CN--N═CH-- or --CH═CH--CH═N--, N being attached to the carbon atomin 4-position of the imidazole ring, said A being represented by A' andsaid intermediates by the formula ##STR23## and the pharmaceuticallyacceptable acid addition salts thereof, wherein L' is a radical offormula --Alk'--CN, --Alk--Y'H, ##STR24## or --Alk--Y--C(═X)--Z'H areuseful as anti-allergic agents.

From formula (I) and (XVIII) it is evident that the compounds of thisinvention may have several asymmetric carbon atoms in their structure.Each of these chiral centers may be present in a R- and aS-configuration, this R- and S-notation being in correspondence with therules described by R. S. Cahn, C. Ingold and V. Prelog in Angew. Chem.,Int. Ed. Engl., 5, 385, 511 (1966).

Pure stereochemically isomeric forms of the compounds of formula (I) and(XVIII) may be obtained by the application of art-known procedures.Diastereoisomers may be separated by physical separation methods such asselective crystallization and chromatographic techniques, e.g., countercurrent distribution, and enantiomers may be separated from each otherby the selective crystallization of their diastereomeric salts withoptically active acids.

Pure stereochemically isomeric forms may also be derived from thecorresponding pure stereochemically isomeric forms of the appropriatestarting materials, provided that the reaction occursstereospecifically.

It is evident that the cis and trans diastereomeric racemates may befurther resolved into their optical isomers, cis(+), cis(-), trans(+)and trans(-) by the application of methodologies known to those skilledin the art.

Stereochemically isomeric forms of the compounds of formula (I) and theintermediates of formula (XVIII) are naturally intended to be embracedwithin the scope of the invention.

The useful antihistaminic properties of the compounds of formula (I) andof the intermediates of formula (XVIII) are demonstrated in thefollowing test procedure.

PROTECTION OF RATS FROM COMPOUND 48/80-INDUCED LETHALITY.

Compound 48/80, a mixture of oligomers obtained by condensation of4-methoxy-N methylbenzeneethanamine and formaldehyde has been describedas a potent histamine releasing agent (Int. Arch. Allergy, 13, 336(1958)). The protection from compound 48/80-induced lethal circulatorycollapse appears to be a simple way of evaluating quantitatively theantihistaminic activity of test compounds. Male rats of an inbred Wistarstrain, weighing 240-260 g were used in the experiment. After overnightstarvation the rats were transferred to conditioned laboratories (temp.=21±1° C, relative humidity =65±5%). The rats were treatedsubcutaneously or orally with a test compound or with the solvent (NaClsolution, 0.9%). One hour after treatment there was injectedintravenously compound 48/80, freshly dissolved in water, at a dose of0.5 mg/kg (0.2 ml/100 g of body weight). In control experiments, wherein250 solvent-treated animals were injected with the standard dose ofcompound 48/80,not more than 2.8% of the animals survived after 4 hours.Survival after 4 hours is therefore considered to be a safe criterion ofa protective effect of drug administration.

The ED₅₀ -values of the compounds of formula (I) and the intermediatesof formula (XVIII) are listed in the first column of table 1 and table2. Said ED₅₀ -values are the values in mg/kg body weight at which thetested compounds protect 50% of the tested animals against compound48/80-induced lethality.

The compounds of formula (I), the intermediates of formula (XVIII) andthe pharmaceutically acceptable acid addition salts thereof are alsopotent serotonin-antagonists.

The potency of the subject compounds as serotonin-antagonists is clearlyevidenced by the results obtained in the following tests wherein theantagonistic activity of the subject compounds on the effect ofserotonin is examined.

ANTAGONISTIC ACTIVITY ON THE EFFECTS OF SEROTONIN IN THE GASTRIC LESIONTEST A. Lesions induced by compound 48/80

Compound 48/80 (a mixture of oligomers obtained by condensation of4-methoxy-N-methylbenzeneethanamine and formaldehyde) is a potentreleaser of vasoactive amines from endogenous stores such as, forexample, histamine and serotonin. Rats injected with compound 48/80exhibit consistent changes of blood flow in different vascular beds:cyanosis of the ears and the extremities are prominent within fiveminutes after injection of the compound; the rats die from shock within30 minutes. The shock, followed by dead, can be avoided if the rats arepretreated with a classical H 1-antagonist. However the stimulatoryeffects on gastric secretion are not suppressed so that rats treatedwith compound 48/80 and protected from shock by an H 1-antagonist mayexhibit all signs of intensive gastric gland activity: gross autopsyshows distended stomachs with abnormal contents and rough bright redpatches all over the mucosa, corresponding to areas of disintegratedglands. A number of known serotonin-antagonists such as, for example,methysergide, cyproheptadine; cinanserin, mianserin, pipamperone,spiperone, pizotifen and metergoline, prevent completely the cyanosis ofears and extremities as well as the lesions in the glandular area of thestomach and the abnormal gastric distension.

B. Method

Male rats of a Wistar inbred strain, weighing 220-250 g, were starvedovernight, water being available ad libitum. The test compounds wereadministered orally as a solution or as a suspension in aqueous medium.A control rat and a "blank" rat received the test compound. One hourlater 5-[4-(diphenylmethyl)-1-piperazinylmethyl]-1-methyl-1H-benzimidazole-2-methanol was administered subcutaneouslyto all rats at the dose of 2.5 mg/kg. Two hours, after the oral orsubcutaneous administration of the test compound, the compound 48/80(freshly solved in water at a concentration of 0.25 mg/ml) was injectedintravenously into all rats (dose: 1 mg/kg) except the "blank" rats.Four hours after the intravenous injection of compound 48/80C., the ratswere decapitated and the stomachs were removed. Subsequently thestomachs were inspected for distension and contents (blood, fluid, food)and thoroughly rinsed. The macroscopic lesions were scored from 0 to+++, 0 corresponding to complete absence of visible lesions and thehighest score corresponding to reddish rough patches covering more thanhalf the glandular area.

The second column of Tables 1 and 2 shows for a number of compounds offormula (I) and the intermediates of formula (XVIII) the doses (in mg/kgbody weight) at which the distension of the stomach as well as thelesions in the glandular area of the stomach are completely absent in50% of the test rats (ED₅₀ -value)

The columns in Tables 1 and 2 with heading "N" illustrate the absence orthe presence of N in the aromatic ring and the place of N in the saidring. In the tables 1 and 2 "b" has the meaning of branch chainedhydrocarbon radicals.

The compounds listed in Tables 1 and 2 are not given for the purpose oflimiting the invention thereto but only to exemplify the usefulpharmacological activities of all the compounds within the scope offormula (I) and of all the intermediates within the scope of formula(XVIII).

    TABLE 1      ##STR25##               Column 1         compound 48/80 Column 2        lethality test     in gastric lesion test       base or rats-ED.sub.50 in mg/kg ED.sub.50     in mg/kg Y m Ar R.sup.1 R.sup.n N salt form body weight body weight       NH 2 3-NH.sub.22-pyridinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- 3HCl 0.08     0.31 NH 2 3-NH.sub.2 CO2-pyridinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- base     0.08 0.16 NH 2 5-Br2-pyridinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- base     0.31 2.5 NH 2 3-Cl2-pyridinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- base 0.16     0.31 NH 2 5-NO.sub.22-pyridinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- base     0.31 2.5 NH 2 5-NH.sub.2 CO2-pyridinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H --     base 0.04 0.08 NH 2 3-Cl2-pyridinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H 1 base     0.08 0.31 NH 2 3-NH.sub.2 CO2-pyridinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H 1     base 0.04 0.04 NH 2 5-NO.sub.2, 6-NH.sub.22-pyridinyl 4-FC.sub.6 H.sub.4     CH.sub.2 H -- base 0.31 2.5 NH 2 3-NH.sub.2      CO2-pyridinyl 2-furanylCH.sub.2 H -- base 0.04 0.63 O 2 5-Br2-pyridinyl     2-furanylCH.sub.2 H -- base 0.31 --      NH 2     ##STR26##      4-FC.sub.6 H.sub.4 CH.sub.2 H -- base 0.04 1.25  NH 2 2-quinolinyl     4-FC.sub.6 H.sub.4      CH.sub.2 H -- base 0.31 -- O 2 2-quinolinyl 4-FC.sub.6 H.sub.4 CH.sub.2     H -- base 1.25 2.5 NH 2 2-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H --     base 0.16 0.63 NH 4 2-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- base     0.16 2.5 NH 3 2-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- base 0.16     -- NH 2 2-pyrimidinyl 2-furanylCH.sub.2 H -- base 0.16 0.04 NH 2 4-Cl,     6-CH.sub.32-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- base 0.63 -- NH     3b 2-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- base 0.63 0.63 NBz 2     2-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- base 0.63 0.63 NMe 2     2-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- base 0.08 0.63 NAc 2     2-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- 2(E)-2-butenedioate 0.04     0.63 NH 2 4-n.C.sub.3 H.sub.7, 6-OH2-pyrimidinyl 4-FC.sub.6 H.sub.4     CH.sub.2 H -- base 0.31 2.5 NH 2 4-OH2-pyrimidinyl 4-FC.sub.6 H.sub.4     CH.sub.2 H -- base 0.08 0.63 NH 2 6-Bz, 4-OH2-pyrimidinyl 4-FC.sub.6     H.sub.4      CH.sub.2 H -- base 0.63 -- NH 2 6-Me, 4-OH2-pyrimidinyl 4-FC.sub.6     H.sub.4 CH.sub.2 H -- H.sub.2 O 0.16 0.63 NH 2 2-pyrimidinyl 4-FC.sub.6     H.sub.4 CH.sub.2 H 4 base 0.02 0.16      ##STR27##      2 2-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- 2(E)-2-butenedioate     0.08 0.63  NH 2 2-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H 3 base 0.08     -- NH 2 2-pyrimidinyl 2-pyridinylCH.sub.2 H -- base 0.04 0.63 NH 2     2-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 2(and 3)F -- base 0.04 0.08 NH     2 2-pyrimidinyl 3-pyridinylCH.sub.2 H -- base 1.25 -- NH 2 2-pyrimidinyl     2-pyrazinylCH.sub.2 H -- base 0.01 0.63 NH 2 2-pyrimidinyl 4-FC.sub.6     H.sub.4 CH.sub.2 H 1 base 0.04 0.08 NH 2 2-pyrimidinyl 2-furanylCH.sub.2     H 1 base 0.04 0.63 NH 2 2-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H 2     2(E)-2-butenedioate 0.16 -- NH 2 2-pyrimidinyl 2-thienylCH.sub.2 H --     base 0.02 2.5 NH 2 2-pyrimidinyl 3-furanylCH.sub.2 H -- base 0.04 0.63     NH 2 2-pyrimidinyl 5-CH.sub.32-furanylCH.sub. 2 H -- base 0.04 0.63 S 2     2-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- base 0.16 0.16 O 2     2-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- base 0.16 0.63 O 2     5-Br2-pyridinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- base 0.16 -- O 2     2-pyrimidinyl 2-furanylCH.sub.2 H -- 2(E)-butenedioate 0.08 1.25 NH 2     2-pyrimidinyl 2-pyridinylCH.sub.2 H 1 1.1/2(E)-butenedioate 0.04 2.5 NH     2 2-Cl4-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- 2HCl.H.sub.2 O 0.31     2.5 NH 2 2-Cl, 6-CH.sub.34-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H --     base 0.08 2.5 NH 2 6-Cl4-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H --     2HCl 0.31 -- NH 2 4-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H --     1/2H.sub.2 O 0.08 1.25 NH 2 2,6-(NH.sub.2).sub.24-pyrimidinyl 4-FC.sub.6     H.sub.4 CH.sub.2 H -- H.sub.2      O 0.08 0.16 NH 2 2-NH, 6-CH.sub.34-pyrimidinyl 4-FC.sub.6 H.sub.4     CH.sub.2 H -- H.sub.2 O 0.31 -- NH 2 6-CH.sub.3      O4-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- base 0.16 -- O 2     2-CH.sub.3 S4-pyrimidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- base 0.16 2.5     NH 2 4-OH, 5-(4-ClC.sub.6 H.sub.4)CH.sub.24-pyrimidinyl 4-FC.sub.6     H.sub.4 CH.sub.2 H -- H.sub.2 O 1.25 2.5 NH 2 4-OH2-quinazolinyl     4-FC.sub.6 H.sub.4 CH.sub.2 H -- base 0.63 2.5 S 2 4-OH2-quinazolinyl    C     4-F.sub.6 H.sub.4 CH.sub.2 H -- H.sub.2 O 0.31 2.5 NH 2 4-quinazolinyl     4-FC.sub.6 H.sub.4      CH.sub.2 H -- base 0.08 2.5 NH 2 2-pyrazinyl 4-FC.sub.6 H.sub.4     CH.sub.2 H -- base 0.16 2.5 NH 2 3-CH.sub.32-quinoxalinyl 4-FC.sub.6     H.sub.4      CH.sub.2 H -- base 1.25 -- O 2 3-CH.sub.32-quinoxalinyl 4-FC.sub.6     H.sub.4 CH.sub.2 H -- base 2.5 -- NH 2 6-Cl3-pyridazinyl 4-FC.sub.6     H.sub.4      CH.sub.2 H -- base 0.08 1.25      ##STR28##             Column 1 Column 2     base or compound 48/80 lethality test in     gastric lesion test L R.sup.1 R.sup.n N salt form rats-ED.sub.50 in     mg/kg body weight ED.sub.50 in mg/kg body weight       1-(2-pyrimidinyl)-4-piperidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H -- base     1.25 -- 1-(2-pyrimidinyl)-3-piperidinyl 4-FC.sub.6 H.sub.4 CH.sub.2 H --     base 1.25 2.5 1-(3-NO.sub.22-pyridinyl)-4-piperidinyl 4-FC.sub.6 H.sub.4     CH.sub.2 H -- 2H.sub.2      O 0.63 --      ##STR29##               Column 1         compound 48/80 Column 2        lethality test     in rats gastric lesion test       base or ED.sub.50 in mg/kg ED.sub.50     in mg/kg Het Y Alk R.sup.1 R.sup.2 A salt form body weight body weight       2-pyrazinyl direct bond (CH.sub.2).sub.2 4-FC.sub.6 H.sub.4 CH.sub.2 H     CHCHCHCH base 0.31 -- 2-pyridinylCH.sub.2 O (CH.sub.2).sub.2 4-FC.sub.6     H.sub.4 CH.sub.2 H CHCHCHCH 2(E)-2-butenedioate 0.08 2.5 2-pyrimidinyl     NH (CH.sub.2).sub.2 4-thiazolylCH.sub.2 H CHCHCHCH 2(E)-butenedioate     0.02 0.08 2-pyrimidinyl NH (CH.sub.2).sub.5 4-FC.sub.6 H.sub.4 CH.sub.2     H CHCHCHCH base 0.31 0.08 2-pyrimidinyl NH (CH.sub.2).sub.2 C.sub.6     H.sub.5      CH.sub.2 H CHCH CHCH base 0.08 0.31 2-pyrimidinyl NH (CH.sub.2).sub.2     4-CH.sub.3C.sub.6 H.sub.4      CH.sub.2 H CHCHCHCH base 0.16 0.63 2-pyrimidinyl NH (CH.sub.2).sub.2     4-ClC.sub.6 H.sub.4 CH.sub.2 H CHCHCHCH base 0.16 2.5 2-pyrimidinyl NH     (CH.sub.2).sub.2 4-CH.sub.3 OC.sub.6 H.sub.4 CH.sub.2 H CHCHCHCH base     0.31 2.5 5-Br2-pyridinyl NH (CH.sub.2).sub.2 C.sub.6 H.sub.5 CH.sub.2 H     CHCHCHCH base 0.31 2.5  2-pyrimidinyl NH (CH.sub.2).sub.2 4-FC.sub.6     H.sub.4      CH.sub.2 H     ##STR30##      base 1.25 2.5  5-Br2-pyridinyl NH (CH.sub.2).sub.2 4-CH.sub.3C.sub.6     H.sub.4 CH.sub.2 H CHCHCHCH base 0.02 0.08      2-pyrimidinyl NH (CH.sub.2).sub.2 4-FC.sub.6 H.sub.4 CH.sub.2 H      ##STR31##      base 0.16 2.5  2-pyrimidinyl NH (CH.sub.2).sub.2 4-OHC.sub.6 H.sub.4     CH.sub.2 H CHCHCHCH base 2.5 2.5 5-NH.sub.2, 6-Cl4-pyrimidinyl NH     (CH.sub.2).sub.2 4-FC.sub.6 H.sub.4 CH.sub.2 H CHCHCHCH base 0.16 1.25     5-NH.sub.24-pyrimidinyl NH (CH.sub.2).sub.2 4-FC.sub.6 H.sub.4 CH.sub.2     H CHCHCHCH base 0.08 0.02  2-pyrimidinyl NH (CH.sub.2).sub.2 4-FC.sub.6     H.sub.4      CH.sub.2 H     ##STR32##      base 1.25 2.5      1-(2-pyridinyl) 4-piperidinyl (CH.sub.2).sub.2 4-FC.sub.6 H.sub.4     CH.sub.2 H CHCHCHCH 1.1/2 (E)-2-butenedioate.H.sub.2      O 0.63 2.5 2-pyrimidinyl NH (CH.sub.2).sub.2 4-FC.sub.6 H.sub.4     CH.sub.2 CH.sub.3 CHCHCHCH base 0.08 0.63 5-Cl2-pyridinyl NCH.sub.3     (CH.sub.2).sub.2 4-FC.sub.6 H.sub.4 CH.sub.2 H CHCHCHCH base 0.31 1.25     5-Cl2-pyridinyl NH (CH.sub.2).sub.3 4-FC.sub.6 H.sub.4 CH.sub.2 H     CHCHCHCH 3HCl.H.sub.2      O 0.63 2.5                                                   Het      ##STR33##       Alk R.sup.1 A base or salt form  ED.sub.50 in mg/kg body weight lethali     ty test in ratscompound 48/80Column 1 body weightED.sub.50 in mg/kg gaste     ric lesion testColumn 2       3-pyridinyl NHCSNH (CH.sub.2).sub.2 4-FC.sub.6 H.sub.4 CH.sub.2     CHCHCHCH base 0.63 0.63 2-pyridinyl NHCSNH (CH.sub.2).sub.2 4-FC.sub.6     H.sub.4 CH.sub.2 CHCHCHCH base 0.63 0.63 3-NH.sub.22-pyridinyl NHCSNH     (CH.sub.2).sub.2 4-FC.sub.6 H.sub.4 CH.sub.2 CHCHCHCH base 0.16 0.31     3     2-Cl-pyridinyl CONH (CH.sub.2).sub.2 4-FC.sub.6 H.sub.4 CH.sub.2     CHCHCHCH 2(E)2-butenedioate.1/2H.sub.2 O 0.16 -- 6-Cl3-pyridinyl CONH     (CH.sub.2).sub.2 4-FC.sub.6 H.sub.4 CH.sub.2 CHCHCHCH 2(E)2-butenedioate     0.31 2.5 2-quinolinyl COO (CH.sub.2).sub.2 4-FC.sub.6 H.sub.4 CH.sub.2   C     CHHCHCH 2(E)2-butenedioate 0.04 0.63 3-NH.sub.22-pyrazinyl CONH (CH.sub.     2).sub.2 4-FC.sub.6 H.sub.4      CH.sub.2 CHCHCHCH base 0.04 0.16

                                      TABLE 2                                     __________________________________________________________________________     ##STR34##                                                                                             Column 1                                                                      compound 48/80                                                                          Column 2                                                            lethality test in                                                                       gastric lesion test                                           base or salt                                                                        rats-ED.sub.50 in mg/kg                                                                 ED.sub.50 in mg/kg                         L'     R.sup.1 R.sup.n                                                                         N form  body weight                                                                             body weight                                __________________________________________________________________________    CH.sub.2 CN                                                                          4-FC.sub.6 H.sub.4 CH.sub.2                                                           --                                                                              4 1/2H.sub.2 O                                                                        0.16      0.63                                       CH.sub.2 CH.sub.2 OH                                                                 4-FC.sub.6 H.sub.4 CH.sub.2                                                           --                                                                              4 base  0.01      0.63                                       CH.sub.2 CH.sub.2 NH.sub.2                                                           4-FC.sub.6 H.sub.4 CH.sub.2                                                           --                                                                              3 H.sub.2 O                                                                           0.16      --                                         CH.sub.2 CH.sub. 2 OH                                                                4-FC.sub.6 H.sub.4 CH.sub.2                                                           --                                                                              3 base  0.31      --                                         CH.sub.2 CN                                                                          4-FC.sub.6 H.sub.4 CH.sub.2                                                           --                                                                              3 H.sub.2 O                                                                           0.63      --                                         __________________________________________________________________________

In view of their antihistaminic and serotonin-antagonistic properties,the compounds of formula (I), the intermediates of formula (XVIII) andtheir acid-addition salts are very useful in the treatment of allergicdiseases such as, for example, allergic rhinitis, allergicconjunctivities, chronic urticaria, allergic astma and the like.

In view of their useful antihistaminic and serotoninantagonisticacitivity, the subject compounds may be formulated into variouspharmaceutical forms for administration purposes. To prepare thepharmaceutical compositions of this invention, an effective amount ofthe particular compound, in base or acid-addition salt form, as theactive ingredient is combined in intimate admixture with apharmaceutically acceptable carrier, which carrier may take a widevariety of forms depending on the form of preparation desired foradministration. These pharmaceutical compositions are desirably inunitary dosage form suitable, preferably, for administration orally,rectally or by parenteral injection. For example, in preparing thecompositions in oral dosage form, any of the usual pharmaceutical mediamay be employed, such as, for example, water, glycols, oils, alcoholsand the like in the case of oral liquid preparations such assuspensions, syrups, elixirs and solutions: or solid carriers such asstarches, sugars, kaolin, lubricants, binders, disintegrating agents andthe like in the case of powders, pills, capsules and tablets. Because oftheir ease in administration, tablets and capsules represent the mostadvantageous oral dosage unit form, in which case solid pharmaceuticalcarriers are obviously employed For parenteral compositions, the carrierwill usually comprise sterile water, at least in large part, thoughother ingredients, for example, to aid solubility, may be included.Injectable solutions, for example, may be prepared in which the carriercomprises saline solution, glucose solution or a mixture of saline andglucose solution. Injectable suspensions may also be prepared in whichcase appropriate liquid carriers, suspending agents and the like may beemployed. Acid addition salts of (I) or (XVIII), due to their increasedwater solubility over the corresponding base form, are obviously moresuitable in the preparation of aqueous compositions.

It is especially advantageous to formulate the aforementionedpharmaceutical compositions in dosage unit form for ease ofadministration and uniformity of dosage. Dosage unit form as used in thespecification and claims herein refers to physically discrete unitssuitable as unitary dosages, each unit containing a predeterminedquantity of active ingredient calculated to produce the desiredtherapeutic effect in association with the required pharmaceuticalcarrier. Examples of such dosage unit forms are tablets (includingscored or coated tablets), capsules, pills, powder packets, wafers,injectable solutions or suspensions, teaspoonfuls, tablespoonfuls andthe like, and segregated multiples thereof.

The present invention is also related with a method of treating allergicdiseases in warm-blooded animals suffering from said allergic diseasesby administering an effective anti-allergic amount of a compound offormula (I) or (XVIII) or a pharmaceutically acceptable acid additionsalt thereof.

Suitable doses administered daily to subjects are varying from 0.1 to100 mg, more preferably from 1 to 50 mg.

The following examples are intented to illustrate and not to limit thescope of the present invention. Unless otherwise stated all partstherein are by weight.

EXAMPLES A. Preparation of Intermediates

The preparation of

N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(4-fluorophenyl)methyl]-H-benzimidazol-2-aminetrihydrochloride;

N-[1-(3-aminopropyl)-4-piperidinyl]-1-[(4-fluorophenyl)methyl]-H-benzimidazol-2-aminetrihydrochloride monohydrate;

1-[(4-fluorophenyl)methyl]-N-[1-[2-[(phenylmethyl)amino]ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine;and

N-[1-(2-chloroethyl)-4-piperidinyl]-1-[(4-fluorophenyl)methyl]-H-benzimidazol-2-aminedihydrochloride is described in U.S. Pat. No. 4,219,559.

EXAMPLE I

(a) A mixture of 15.7 parts of 1-chloro-2-nitrobenzene, 9.7 parts of2-furanmethanamine, 8.4 parts of sodium hydrogen carbonate and 45 partsof N,N-dimethylacetamide was stirred overnight at about 120° C. Thereaction mixture was cooled, water was added and the product wasextracted with 1,1'-oxybisethane. The extract was dried, filtered andevaporated. The residue was purified by column-chromatography oversilica gel using trichloromethane as eluent. The pure fractions werecollected and the eluent was evaporated. The oily residue was trituratedin petroleumether. The product was filtered off and dried, yielding 15parts of N-(2-nitrophenyl)-2-furanmethanamine; mp. 85.6° C.(intermediate 1).

(b) A mixture of 40 parts of 5-methyl-2-furanmethanamine, 46 parts of1-chloro-2-nitrobenzene and 210 parts of N,N-diethylethanamine wasstirred and refluxed for 2 days. The reaction mixture was evaporated,water was added and the product was extracted with dichloromethane. Theextract was dried, filtered and evaporated. The residue was purified byfiltration over silica gel using trichloromethane as eluent. Thefiltrate was evaporated, yielding 62 parts (89%) of5-methyl-N-(2-nitrophenyl)-2-ftranmethanamine as a residue (intermediate2).

(c) A mixture of 50 parts of 2-chloro-3-nitropyridine, 32.5 parts of2-pyridinemethanamine, 53 parts of sodium carbonate and 675 parts ofN,N-dimethylacetamide was stirred for 1 hour at 100° C. The reactionmixture was cooled and filtered over Hyflo. The filtrate was poured onto1000 parts of water and the whole was stirred overnight at roomtemperature. The product was filtered off and dried, yielding 56.4 partsof N-(3-nitro-2-pyridinyl)-2-pyridinemethanamine; mp. 113.6° C.(intermediate 3).

Following the procedure described in c) there were also prepared:

N-[(4-fluorophenyl)methyl]-4-nitro-3-pyridinamine, 1-oxide (intermediate4);

2-nitro-N-(2-thienylmethyl)benzenamine (intermediate 5);

N-(2-nitrophenyl)-3-furanmethanamine (intermediate 6); and

4-fluoro-N-(5-methoxy-2-nitrophenyl)benzenemethanamine (intermediate 7).

EXAMPLE II

A mixture of 62 parts of 5-methyl-N-(2-nitrophenyl)-2-furanmethanamine,2 parts of a solution of thiophene in metbanol 4% and 400 parts ofmethanol, saturated with ammonia, was hydrogenated at normal pressureand at room temperature with 4 parts of palladium-on-charcoal catalyst10%. After the calculated amount of hydrogen was taken up, the catalystwas filtered off and the filtrate was evaporated, yielding 50.5 parts(95%) of N¹ -[(5-methyl-2-furanyl)methyl]-1,2-benzenediamine as aresidue (intermediate 8).

In a similar manner there were also prepared:

N⁴ -[(4-fluorophenyl)methyl]-3,4-pyridinediamine; mp. 163.7° C.(intermediate 9);

N³ -[(4-fluorophenyl methyl]-3,4-pyridinediamine monohydrochloride; mp.208.9° C. (intermediate 10);

N² -(2-pyridinylmethyl)-2,3-pyridinediamine; mp. 134.9° C. (intermediate11);

N-(3-furanylmethyl)-1,2-benzenediamine as a residue; (intermediate 12);

N¹ _(s) 2-thienylmethyl)-1,2-benzenediamine as a residue; (intermediate13);

N² -(2-furanylmethyl)- 2,3-pyridinediamine as a residue; (intermediate14);

N-(2-furanylmethyl)-1,2-benzenediamine as a residue; (intermediate 15);and

N² -[(4-fluorophenyl)methyl]-4methoxy-1,2-benzenediamine as a residue(intermediate 16).

EXAMPLE III

To a stirred and cooled (0° C.) solution of 8.7 parts ofN-[(4-fluorophenyl)methyl]-4-nitro-3-pyridinamine, 1-oxide and 150 partsof trichloromethane was added dropwise a solution of 10.2 parts ofphosphor trichloride in 75 parts of trichloromethane. Upon completion,the mixture was allowed to reach room temperature and stirring wascontinued for 1 hour at reflux temperature. The reaction mixture wascooled and the solvent was evaporated. The residue was stirred intrichloromethane. The product was filtered off and dried, yielding 9parts of N-[(4-fluorophenyl)methyl]-4-nitro-3-pyridinaminemonohydrochloride (intermediate 17).

EXAMPLE IV

A mixture of 3 parts of 2,3-pyridinediamine and 4 parts of1-(chloromethyl)-4-fluorobenzene was stirred overnight at 120° C.Trichloromethane and a dilute ammonium hydroxide solution were added andthe product was extracted. The organic phase was washed with water,dried, filtered and evaporated. The residue was purified bycolumn-chromatography over silica gel using a mixture oftrichloromethane and methanol (90:10 by volume) as eluent. The secondfraction was collected and the eluent was evaporated, yielding 1.8 partsof N³ -[(4-fluorophenyl)methyl]-2,3-pyridinediamine as a residue(intermediate 18)

EXAMPLE V

A mixture of 54 parts of ethyl 4-isothiocyanato-1-piperidinecarboxylate,48 parts of N² -(2-furanylmethyl)-2,3-pyridinediamine and 450 parts oftetrahydrofuran was stirred and refluxed overnight. The reaction mixturewas evaporated and the residue was crystallized from a mixture of2-propanone and 2,2'-oxybispropane. The product was filtered off anddried, yielding 76 parts (75%) of ethyl4-[[[2-[(2-furanylmethyl)amino]-3-pyridinyl]aminothioxomethyl]amino]-1-piperidinecarboxylate;mp. 132.7° C. (intermediate 19)

In a similar manner there were also prepared:

ethyl4-[[[2-[(2-furanylmethyl)amino]phenyl]aminothioxomethyl]amino]-1-piperidinecarboxylateas a residue (intermediate 20);

ethyl4-[[[3-[[(4-fluorophenyl)methyl]amino]-2-pyridinyl]-aminothioxomethyl]amino]-1-piperidinecarboxylateas a residue (intermediate 21);

ethyl4-[[[4-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]-aminothioxomethyl]amino]-1-piperidinecarboxylate;mp. 166° C. (intermediate 22);

ethyl4-[[[3-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]-aminothioxomethyl]amino]-1-piperidinecarboxylateas a residue (intermediate 23);

ethyl4-[[[2-[(2-pyridinylmethyl)amino]-3-pyridinyl]aminothioxomethyl]amino]-1-piperidinecarboxylateas a residue (intermediate 24);

ethyl4-[[[2-[(2-thienylmethyl)amino]phenyl]aminothioxomethyl]amino]-1-piperidinecarboxylateas a residue (intermediate 25);

ethyl4-[[[2-[(3-furanylmethyl)amino]phenyl]aminothioxomethyl]amino]-1-piperidinecarboxylateas a residue (intermediate 26);

ethyl4-[[[2-[[(5-methyl-2-furanyl)methyl]amino]phenyl]-aminothioxomethyl]amino]-1-piperidinecarboxylateas a residue (intermediate 27);

ethyl4-[[[2-[[(4-methoxyphenyl)methyl]amino]phenyl]-aminothioxomethyl]amino]-1-piperidinecarboxylateas a residue (intermediate 28); and

ethyl4-[[1-[(4-fluorophenyl)methyl]-6methoxy-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate(intermediate 29);

EXAMPLE VI

A mixture of 42.5 parts of ethyl4-[(phenylmethyl)amino]-1-piperidinecarboxylate, 30 parts of1-isothiocyanato-2-nitrobenzene and 270 parts of tetrahydrofuran wasstirred for 3 hours at room temperature. 2,2'-Oxybispropane was addedand stirring was continued overnight. The precipitated product wasfiltered off and dried, yielding 48.5 parts (68.5%) of ethyl4-[[[2-nitrophebyl)-amino]thioxomethyl](phenylmethyl)amino]-1-piperidinecarboxylate;mp. 140° C.; (intermediate 30).

EXAMPLE VII

A mixture of 48.5 parts of ethyl4-[[[2-nitrophenyl)amino]-thioxomethyl](phenylmethyl)amino]-1-piperidinecarboxylateand 600 parts of methanol, saturated with ammonia, was hydrogenated atnormal pressure and at 30° C. with 15 parts of palladium-on-charcoalcatalyst 10%. After the calculated amount of hydrogen was taken up, thecatalyst was filtered off over Hyflo and the filtrate was evaporated,yielding 47 parts (100%) of ethyl4-[[[2-aminophenyl)-amino]thioxomethyl](phenylmethyl)amino]-1-piperidinecarboxylateas a residue (intermediate 31).

EXAMPLE VIII

A mixture of 74 parts of ethyl4-[[[2-[(2-furanylmethyl)amino]-3-pyridinyl]aminothioxomethyl]amino]-1-piperidinecarboxylate,96 parts of mercury (II) oxide, 0.1 parts of sulfur and 800 parts ofethanol was stirred and refluxed for 3 hours. The reaction mixture wasfiltered over Hyflo and the filtrate was evaporated. The residue wascrystallized from acetonitrile, yielding 52.5 parts (79%) of ethyl4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinecarboxylate; mp. 149.2° C. (intermediate 32).

Following the same cyclizing-procedure there were also prepared:

ethyl4-[[1-(2-furanylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate;mp. 135.8° C. (intermediate 33);

ethyl 4-[[1-[(4-fluorophenyl)methyl]-1H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinecarboxylate; mp. 212.5° C. (intermediate 34);

ethyl 4-[[1-[(4-fluorophenyl)methyl]-1H-imidazo[4,5-c]pyridin-2-yl]amino]-1-piperidinecarboxylate dihydrochloride monohydrate;(intermediate 35);

ethyl 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-c]pyridin-2-yl]amino]-1-piperidinecarboxylate dihydrochloride monohydrate; mp. 168.6°C. (intermediate 36);

ethyl 4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]-amino]-1-piperidinecarboxylate; mp. 141.3° C. (intermediate 37);

ethyl4-[[1-(2-thienylmethyl)-1H-benzimidazol-2-yl]amino]-piperidinecarboxylate;mp. 142.7° C. (intermediate 38);

ethyl4-[[1-(3-furanylmethyl)-1H-benzimidazol-2-yl]amino-]1-piperidinecarboxylate;mp. 150.7° C. (intermediate 39);

ethyl4-[[1-[(5-methyl-2-furanyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylatehemihydrate; mp. 150.120 C. intermediate 40);

ethyl4-[[1-[(4-methoxyphenyl)methyl]-1H-benzimidazol-2-yl]-amino]-1-piperidinecarboxylate;mp. 157.1° C. (intermediate 4); and

ethyl4-[(1H-benzimidazol-2-yl)(phenylmethyl)amino]-1-piperidinecarboxylate(intermediate 42).

EXAMPLE IX

A mixture of 15.03 parts of ethyl4-(5-fluoro-1H-benzimidazol-2-ylamino)-1-piperidinecarboxylate, 9 partsof 1(chloromethyl)-4-fluorobenzene, 5.3 parts of sodium carbonate, 0.2parts of potassium iodide and 117 parts of N,N-dimethylformamide wasstirred and heated over week-end at 70° C. The reaction mixture wascooled and poured onto water. The product was extracted twice withmethylbenzene. The combined extracts were dried, filtered andevaporated. The residue was crystallized from a mixture of 2-propanoneand 2,2'-oxybispropane. The product was filtered off and dried, yielding13.4 parts (62.1%) of ethyl4-[[5(6)-fluoro-1-(4-fluorophenylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate;mp. 182.5° C. (intermediate 43).

In a similar manner there were also prepared:

ethyl4-[[1-[(2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate;mp. 161.5° C. (intermediate 44);

ethyl4-[[1-(3-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate;mp. 191.4° C. (intermediate 45);

ethyl4-[[1-(2-pyrazinylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylatedihydrobromide monohydrate; mp. 178.5°-179.3° C. (intermediate 46);

ethyl4-[[1-(4-thiazolylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate;mp. 156.2° C. (intermediate 47);

ethyl4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-methylamino]-1-piperidinecarboxylateas a residue (intermediate 48); and

ethyl4-[[1-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-benziemidazol-2-yl]amino]-1-piperidinecarboxylatedihydrochloride; mp. 2.33.7° C. (intermediate 49).

EXAMPLE X

A mixture of 50 parts of ethyl4-[[3-(2-furanylmethyl)-31H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinecarboxylate,50 parts of potassium hydroxide, 400 parts of 2-propanol and 20 drops ofwater was stirred and refluxed for about 5 hours. The reaction mixturewas evaporated and water was added to the residue. The product wasextracted twice with 4-methyl-2-pentanone. The combined extracts weredried, filtered and evaporated. The solid residue was stirred in1,1'-oxybisethane. The product was filtered off and dried, yielding 34parts (85%) of3-(2-furanylmethyl)-N-(4-piperidinyl)-31H-imidazo[4,5-b]pyridin-2-amine;mp. 159.0° C. (intermediate 50).

Following the same procedure there were also prepared:

1-(2-furanylmethyl)-N-(4-piperidinyl)-1H-benzimidazol-2-amine; mp.211.0° C. (intermediate 51);

N-(4-piperidinyl)-1-(2-thienylmethyl)-1H-benzimidazol-2-amine;(intermediate 52);

1-(3-furanylmethyl)-N-(4-piperidinyl)-1H-benzimidazol-2-amine;(intermediate 53);

1-[(5-methyl-2-furanyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-amineas a residue (intermediate 54);

1-[(4-methoxyphenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-amine;mp. 178.1° C. (intermediate 55);

1-[(4-fluorophenyl)methyl]-5-methoxy-N-(4-piperidinyl)-1H-benzimidazol-2-amine(intermediate 56);

1-[(4-fluorophenyl)methyl]-N-methyl-N-(4-piperidinyl)-1H-benzimidazol-2-aminedihydrochloride monohydrate; mp. 222.2° C. (intermediate 57);

1-[(4-fluorophenyl)methyl]-6-methoxy-N-(4-piperidinyl)-1H-benzimidazol-2-amine(intermediate 58); and

N-(phenylmethyl)-N-(4-piperidinyl)-1H-benzimidazol-2-amine;(intermediate 59).

EXAMPLE XI A mixture of 30 parts of ethyl4-[[1-[(2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylateand 300 parts of a hydrobromic acid solution 48% in water was stirredand heatsd for 3 hours at 80° C. The reaction mixture was evaporated andthe residue was crystallized from methanol, yielding 41 parts (93.2%) ofN-(4-piperidinyl)-1-[(2-pyridinyl)methyl]-1H-benzimidazol-2-aminetrihydrobromide; mp. 295.9° C. (intermediate 60).

Following the same procedure there were also prepared:

N-(4-piperidinyl)-1-(3-pyridinylmethyl)-1H-benzimidazol-2-aminetrihydrobromide; mp. 260° C. (intermediate 61);

N-(4-piperidinyl)-1-(2-pyrazinylmethyl)-1H-benzimidazol-2-aminetrihydrobromide; (intermediate 62);

1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-imidazo-[4,5-b]pyridin-2-aminedihydrobromide; mp. +300.6° C. (intermediate 63);

1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-imidazo-[4,5-c]pyridin-2-aminedihydrobromide; mp. 279.4° C. (intermediate 64);

N-(4-piperidinyl)-3-(2-pyridinylmethyl)-31H-imidazo[4,5-1]-pyridin-2-aminetrihydrobromide; mp. 265.5° C. (intermediate 65);

3-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-31H-imidazo-[4,5-c]pyridin-2-aminedihydrobromide monohydrate; mp. 291.6° C. (intermediate 66);

N-(4-piperidinyl)-1-(4-thiazolylmethyl)-1H-benzimidazol-2aminedihydrobromide monohydrate; mp. 223.5° C. (intermediate 67); and

1-[(5-methyl-1H-imidazol-4-yl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-aminetrihydrobromide; mp. 272.1° C. (intermediate 68).

EXAMPLE XII

To 2 parts of a solution of 2 parts of thiophene in 40 parts of ethanolwere added 15 parts of ethyl 4-oxo-1-piperidinecarboxylate, 25 parts of1-(4-fluorophenylmethyl)-N-(4-piperidinyl)-1H-benzimidazol-2-amine and200 parts of methanol. The whole was hydrogenated at normal pressure andat room temperature with 5 parts of platinum-on-charcoal catalyst 5%.After the calculated amount of hydrogen was taken up, the catalyst wasfiltered off and the filtrate was evaporated. The residue was purifiedby column-chromatography over silica gel using a mixture oftrichloromethane and methanol (90:10 by volume) as eluent. The purefractions were collected and the eluent was evaporated. The residue wasconverted into the hydrochloride salt in 2-propanol and 2-propanone. Thesalt was filtered off and dried, yielding 13.6 parts of ethyl4-[1-(4-fluorophenylmethyl)-1H-benzimidazol-2-yl-amino][1,4'-bipiperidine]-1'-carboxylate dihydrochloride monohydrate mp. 260°C. (intermediate 69).

A mixture of 25 parts of 1-(phenylmethyl)-3-piperidinone hydrochloride,55 parts of1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-aminedihydrobromide, 1 part of a solution of thiophene in ethanol 4%, 50parts of potassium acetate and 500 parts of 2-methoxyethanol washydrogenated at normal pressure and at 50° C. with 5 parts ofpalladium-on-charcoal catalyst 10%. After the calculated amount ofhydrogen was taken up, the catalyst was filtered off and the filtratewas evaporated. The residue was taken up in water and the whole wasalkalized with sodium hydroxide. The product was extracted withdichloromethane. The extract was dried, filtered and evaporated. Theresidue was crystallized twice from acetonitrile. The product wasfiltered off and dried, yieldi 9.75 parts of1-[(4-fluorophenyl)methyl]-N-[1'-(phenylmethyl)-[1,3'-bipiperidin]-4-yl]-1H-benzimidazol-2-amine;mp. 174.6° C. (intermediate 70).

EXAMPLE XIII

A mixture of 21 parts of ethyl4-[1-(4-fluorophenylmethyl)-1H-benzimidazol-2-ylamino][1,4'-bipiperidine]-1'-carboxylateand 450 parts of hydrobromic acid solution 48% was stirred and refluxedfor 16 hours. The reaction mixture was evaporated. From the residue thefree base was liberated in the conventional manner with sodium hydroxidein water and extracted with dichloromethane. The extract was dried,filtered and evaporated, yielding 8 parts (50%) ofN-[1-(4-fluorophenylmethyl)-1H-benzimidazol-2-yl][1,4'-bipiperidine]-4-amineas a residue (intermediate 71).

EXAMPLE XIV

A mixture of 11.3 parts of1-[(4-fluorophenyl)methyl]-N-[1'-(phenylmethyl)-[1,3'-bipiperidin]-4-yl]-1H-benzimidazol-2-amineand 200 parts of methanol was hydrogenated at normal pressure and atroom temperature with 2 parts of palladium-on-charcoal catalyst 10%.After the calculated amount of hydrogen was taken up, the catalyst wasfiltered off and the filtrate was evaporated. The residue was suspendedin 2,2'-oxybispropane. The product was filtered off and dried, yielding8.5 parts (91.5%) of N([1,3'-bipiperidin]-4-yl)-1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-amine(intermediate 72).

EXAMPLE XV

A mixture of 2.7 parts of 2-chloroacetonitrile, 19.5 parts ofN-(4-piperidinyl)-1-(3-pyridinylmethyl)-1H-benzimidazol-2-aminetrihydrobromide, 13 parts of sodium carbonate and 135 parts ofN,N-dimethylformamide was stirred and heated for 3 hours at 50° C. Thereaction mixture was poured onto water and extracted withdichloromethane. The extract was dried, filtered and evaporated. Theresidue was crystallized from acetonitrile, yielding 6 parts (50%) of4-[[1-(3-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidineacetonitrilehemihydrate; mp. 204.5° C. (intermediate 73).

Following the same procedure and using equivalent amounts of theappropriate starting materials there were also prepared:

    __________________________________________________________________________     ##STR35##                                                                    Comp.                                   base or salt                          No. n A          R.sup.1      R.sup.2                                                                            R.sup.3                                                                            form  mp. in °C.               __________________________________________________________________________    74  3 CHCHCHCH   4-FC.sub.6 H.sub.4 CH.sub.2                                                                H    H    base  130.5                           75  1 CHCHCHCH   (2-pyridinyl)CH.sub.2                                                                      H    H    base  152.6                           76  1 CHCHCHCH   4-FC.sub.6 H.sub.4 CH.sub.2                                                                H    5(6)-F                                                                             base  176.7                           77  1 NCHCHCH    4-FC.sub.6 H.sub.4 CH.sub.2                                                                H    H    base  183.7                           78  1 CHCHCHCH   (2-pyrazinyl)CH.sub.2                                                                      H    H    base  195.8                           79  1 CHCHCHN    4-FC.sub.6 H.sub.4 CH.sub.2                                                                H    H    1/2H.sub.2 O                                                                        173.9                           80  1 CHCHCHCH   (2-fyranyl)CH.sub. 2                                                                       H    H    base  194.4                           81  1 CHCHNCH    4-FC.sub.6 H.sub.4 CH.sub.2                                                                H    H    H.sub.2 O                                                                           188.5                           82  1 NCHCHCH    (2-pyridinyl)CH.sub.2                                                                      H    H    base  170.0                           83  1 NCHCHCH    (2-furanyl)CH.sub.2                                                                        H    H    base  157.0                           84  1 CHCHCHCH   (2-thienyl)CH.sub.2                                                                        H    H    base  191.7                           85  1 CHNCHCH    4-FC.sub.6 H.sub.4 CH.sub.2                                                                H    H    base  --                              86  1 CHCHCHCH   (3-furanyl)CH.sub.2                                                                        H    H    base  184.0                           87  1 CHCHCHCH   (5-CH.sub.32-furanyl)CH.sub.2                                                              H    H    base  177.3                           88  4 CHCHCHCH   4-FC.sub.6 H.sub.4 CH.sub.2                                                                H    H    base  144.0                           89  1 CHCHCHCH   CH.sub.3     H    H    base  212.3                           90  1 CHCHCHCH   C.sub.6 H.sub.5 CH.sub.2                                                                   H    H    base  180.4                           91  1 CHCHCHCH   4-CH.sub.3C.sub.6 H.sub.4 CH.sub.2                                                         H    H    base  155.2                           92  1 CHCHCHCH   4-ClC.sub.6 H.sub.4 CH.sub.2                                                               H    H    base  180.4                           93  1 CHCHCHCH   4-CH.sub.3 OC.sub.6 H.sub.4 CH.sub.2                                                       H    H    base  169.9                           94  1 CHCHCHCH   4-FC.sub.6 H.sub.4 CH.sub.2                                                                H    5-CH.sub.3 O                                                                       base  174.8                           95  1 CHCHCHCH   4-FC.sub.6 H.sub.4 CH.sub.2                                                                CH.sub.3                                                                           H    base  157.4                           96  1 CHCHCHCH   4-FC.sub.6 H.sub.4 CH.sub.2                                                                H    6-CH.sub.3 O                                                                       base  222                             97  1 CHCHCHCH   H            C.sub.6 H.sub.5 CH.sub.2                                                           H    base  --                              98  1 CHCHCHCH   (5-CH.sub.34-imidazolyl)CH.sub.2                                                           H    H    base  247.1                           99  1 CHCHCHCH   H            H    H    base  226                             __________________________________________________________________________

In a similar manner there was also prepared:

(cis+trans)-4-[[1-[(4-fluoropenyl)methyl]-1H-benzimidazol-2-yl]amino]-3-methyl-1-piperidineacetonitrile;mp. 150.1° C. (intermediate 100).

EXAMPLE XVI

To a stirred mixture of 3.14 parts of 3-furancarboxylic acid, 6 parts ofN,N-diethylethanamine and 390 parts of dichloromethane were added 7.2parts of 2-chloro-1-methylpyridinium iodide. After stirring for 10minutes at room temperature, 7 parts of4-[(1H-benzimidazol-2-yl)amino]-1-piperidineacetonitrile were added andthe whole was stirred for 1 hour at room temperature. The reactionmixture was washed with water. The organic phase was dried, filtered andevaporated. The residue was crystallized from acetonitrile, yielding 7parts (74%) of4-[[1-(3-furanylcarbonyl)-1H-benzimidazol-2-yl]amino]-1-piperidineacetonitrile(intermediate 101).

EXAMPLE XVII

A mixture of 17 parts of4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidineacetonitrileand 400 parts of methanol, saturated with ammonia, was hydrogenated atnormal pressure and at room temperature with 3 parts of Raney-nickelcatalyst. After the calculated amount of hydrogen was taken up, thecatalyst was filtered off and the filtrate was evaporated. The residuewas crystallized from acetonitrile, yielding 15 parts (90%) ofN-[1-(2-aminoethyl)-4-piperidinyl]-3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-amine;mp. 151.1° C. (intermediate 102).

Following the same procedure and using equivalent amounts of theappropriate starting materials there were also prepared:

    __________________________________________________________________________     ##STR36##                                                                    Comp.                                   base or salt                          No. n A          R.sup.1      R.sup.2                                                                            R.sup.3                                                                            form    mp. in °C.             __________________________________________________________________________    103 4 CHCHCHCH   4-FC.sub.6 H.sub.4 CH.sub.2                                                                H    H    base    --                            104 2 NCHCHCH    4-FC.sub.6 H.sub.4 CH.sub.2                                                                H    H    base    174.5                         105 2 CHCHCHCH   (2-pyridinyl)CH.sub.2                                                                      H    H    base    145.1                         106 2 CHCHCHCH   4-FC.sub.6 H.sub.4 CH.sub.2                                                                H    5(6)-F                                                                             base    171                           107 2 CHCHCHCH   (3-pyridinyl)CH.sub.2                                                                      H    H    base    150.7                         108 2 CHCHCHN    4-FC.sub.6 H.sub.4 CH.sub.2                                                                H    H    H.sub.2 O                                                                             116.9                         109 2 CHCHCH CH  (2-pyrazinyl)CH.sub.2                                                                      H    H    base    169.3                         110 2 CHCHCHCH   (2-furanyl)CH.sub.2                                                                        H    H    base    163.0                         111 2 CHNCHCH    4-FC.sub.6 H.sub.4 CH.sub.2                                                                H    H    H.sub.2 O                                                                             185.0                         112 2 NCHCHCH    (2-furanyl)CH.sub.2                                                                        H    H    3(E)2-butene-                                                                         182                                                                   dioate H.sub.2 O                      113 2 CHCHCHCH   (2-thienyl)CH.sub.2                                                                        H    H    base    137.1                         114 2 CHNCHCH    4-FC.sub.6 H.sub.4 CH.sub.2                                                                H    H    base    --                            115 2 CHCHCHCH   (3-furanyl)CH.sub.2                                                                        H    H    base    158.1                         116 2 CHCHCHCH   (5-CH.sub.32-furanyl)CH.sub.2                                                              H    H    base    --                            117 5 CHCHCHCH   4-FC.sub.6 H.sub.4 CH.sub.2                                                                H    H    base    172.9                         118 2 CHCHCHCH   CH.sub.3     H    H    base    199.0                         119 2 CHCHCHCH   C.sub.6 H.sub.5 CH.sub.2                                                                   H    H    base    131.6                         120 2 CHCHCHCH   4-ClC.sub.6 H.sub.4 CH.sub.2                                                               H    H    base    143.4                         121 2 CHCHCHCH   4-CH.sub.3C.sub.6 H.sub.4 CH.sub.2                                                         H    H    3(E)2-butene-                                                                         260                                                                   dioate                                122 2 CHCHCHCH   4-CH.sub.3 OC.sub.6 H.sub.4 CH.sub.2                                                       H    H    base    129.8                         123 2 CHCHCHCH   4-FC.sub.6 H.sub.4 CH.sub.2                                                                H    5-CH.sub.3 O                                                                       base    --                            124 2 CHCHCHCH   4-FC.sub.6 H.sub.4 CH.sub.2                                                                H    6-CH.sub.3 O                                                                       base    --                            125 2 CHCHCHCH   4-FC.sub.6 H.sub.4 CH.sub.2                                                                CH.sub.3                                                                           H    base    --                            126 2 CHCHCHCH   (5-CH.sub.34-imidazolyl)CH.sub.2                                                           H    H    base    190 and                       127 2 CHCHCHCH   H            C.sub.6 H.sub.5 CH.sub.2                                                           H    base    182.8                         __________________________________________________________________________

In a similar manner there was also prepared:

(cis+trans)-N-[1-(2-aminoethyl)-3-methyl-4-piperidinyl]-1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-amine;mp. 132.2° C. (intermediate 128).

EXAMPLE XVIII

To 180 parts of tetrahydrofuran were added carefully 2.4 parts oflithium aluminium hydride under nitrogen atmosphere. Then there wasadded dropwise a solution of 7 parts of4-[[1-(3-furanylcarbonyl)-1H-benzimidazol-2-yl]amino]-1-piperidineacetonitrilein tetrahydrofuran: temp. rose to 50° C. Upon completion, stirring wascontinued overnight at reflux temperature. The reaction mixture wascooled in an ice-bath and decomposed by the successive additions of 3parts of water, 9 parts of a sodium hydroxide solution 15% and 9 partsof water. The whole was filtered over Hyflo and the filtrate wasevaporated. The residue was purified by filtration over silica gel usinga mixture of trichloromethane and methanol (80:20 by volume) saturatedwith ammonia, as eluent. The pure fractions were collected and theeluent was evaporated. The residue was crystallized from acetonitrile,yielding 3.6 parts (69.5%) ofN-[1-(2-aminoethyl)-4-piperidinyl]-1H-benzimidazol-2-amine; mp. 99.8° C.(intermediate 129).

EXAMPLE XIX

A mixture of 9.25 parts of 1-chloro-2-propanone, 48.6 parts of1-(4-fluorophenylmethyl)-N-(4-piperidinyl)-1H-benzimidazol-2-aminedihydrobromide, 32 parts of sodium carbonate and 135 parts ofN,N-dimethylformamide was stirred and heated overnight at 50° C. Thereaction mixture was poured onto water and the product was extractedwith 4-methyl-2-pentanone. The extract was dried, filtered andevaporated. The residue was crystallized from 4-methyl-2-pentanone,yielding 15 parts (39.5%) of1-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]-2-propanone(intermediate 130).

A mixture of 5.7 parts of1-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]-2-propanone,2.1 parts of hydroxylamine hydrochloride, 20 parts of pyridine, 10 partsof ethanol and 12.5 parts of water was stirred for 3 hours at 65° C. Thereaction mixture was poured onto water and the whole was alkalized withsodium hydroxide. The product was filtered off and dried, yielding 5.5parts (93%) of1-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]-2-propanone,oxime; mp. 202° C. (intermediate 131).

A mixture of 4 parts of1-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]-2-propanone,oxime and 120 parts of methanol, saturated with ammonia, washydrogenated at normal pressure and at room temperature with 2 parts ofRaney-nickel catalyst. After the calculated amount of hydrogen was takenup, the catalyst was filtered off and the filtrate was evaporated. Theresidue was crystallized from acetonitrile, yielding 1.3 parts (34%) ofN-[1-(2-aminopropyl)-4-piperidinyl]-1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-amine,mp. 178.3° C. (intermediate 132).

EXAMPLE XX

A mixture of 5.4 parts of ethyl (2-chloroethyl)carbamate, 19 parts ofN-(4-piperidinyl)-1-(4-thiazolylmethyl)-1H-benzimidazol-2-aminetrihydrobromide monohydrate, 15 parts of sodium carbonate, 0.2 parts ofsodium iodide and 90 parts of N,N-dimethylacetamide was stirredovernight at about 75° C. Water was added and the product was extractedwith 4-methyl-2-pentanone. The extract was dried, filtered andevaporated, yielding 14 parts of ethyl[2-[4-[[1-(4-thiazolylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]carbamateas an oily residue (intermediate 133)

A mixture of 14 parts of ethyl [2-[4-[[1-(4-thiazolylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]carbamate and 300 partsof a hydrobromic acid solution 48% in water was stirred and refluxed for30 minutes. The reaction mixture was evaporated. The sticky residuesolidified in a mixture of ethanol and acetonitrile. The product wasfiltered off and dried, yielding 14 parts ofN-[1-(2-aminoethyl)-4-piperidinyl]-1-(4-thiazolylmethyl)-1H-benzimidazol-2-amine trihydrobromide (intermediate 134).

EXAMPLE XXI

To 1 part of a solution of 2 parts of thiophene in 40 parts of ethanolwere added 11.3 parts of1-(4-fluorophenylmethyl)-N-[1-[2-[(phenylmethyl)amino]ethyl]-4-piperidinyl]-1H-benzimidazol-2amine,2 parts of paraformaldehyde, 10 parts of potassium acetate ard 120 partsof methanol. The whole was hydrogenated at normal pressure and at roomtemperature with 2 parts of platinum-on-charcoal catalyst 10%. After thecalculated amount of hydrogen was taken up, the catalyst was filteredoff over Hyflo and the filtrate was evaporated, yielding 9.4 parts of1-[(4-fluorophenyl)methyl]-N-[1-[2-[methyl(phenylmethyl)amino]ethyl]-4-piperidinyl]-1H-benzimidazol-2-amineas a residue (intermediate 135).

A mixture of 9.4 parts of 1-[(4-fluorophenyl)methyl]-N-]N[1-[2-(methyl(phenylmethyl)amino]ethyl]-4-piperidinyl]-1H-benzimidazol-2-amineand 120 parts of methanol was hydrogenated at normal pressure and atroom temperature with 2 parts of palladium-on-charcoal catalyst 10%.After the calculated amount of hydrogen was taken up, the catalyst wasfiltered off and the filtrate was evaporated. The residue was convertedinto the hydrochloride salt in 2-propanol. The salt was filtered off anddried, yielding 6.3 parts (64%) of1-[(4-fluorophenyl)methyl]-N-[1-[2-(methylamino)ethyl]-4-piperidinyl]-1H-benzimidazol-2mp.232.4° C. (intermediate 136).

EXAMPLE XXII

During one hour, gaseous oxirane was bubbled through a stirred mixtureof 6 parts of1-(2-furanylmethyl)-N-(4-piperidinyl)-1H-benzimidazol-2-amine and 40parts of methanol. Stirring was continued for 3 hours at roomtemperature. The reaction mixture was evaporated and the oily residuewas converted into the (E)-2-butenedioate salt in ethanol and2-propanone. The salt was filtered off and dried, yielding 6.5 parts of4-[[1-(2-furanylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidineethanol(E)-2-butenedioate (2:3) monohydrate; mp. 183.2° C. (intermediate 137).

In a similar manner there was also prepared:

4-[1-(4-fluorophenylmethyl)-1H-benzimidazol-2-ylamino]-1-piperidineethanol;mp. 138.7° C. (intermediate 138).

EXAMPLE XXIII

A mixture of 7.5 parts ofN-[1-(2-aminoethyl)-4-piperidinyl]-1-[(4-methoxyphenyl)methyl]-1H-benzimidazol-2-amineand 225 parts of a hydrobromic acid solution 48% in water was stirredand heated over week-end. After cooling, the precipitated product wasfiltered off and dried, yielding 7.3 parts (57%) of4-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-1H-benzimidazol-1-yl]methyl]phenoltrihydrobromide monohydrate; mp. >250° C. (intermediate 139).

EXAMPLE XXIV

A mixture of 12 parts ofN-[1-(2-aminoethyl)-4-piperidinyl]-1-[(4-fluorophenyl)methyl]-5-methoxy-1H-benzimidazol-2-amineand 150 parts of a hydrobromic acid solution 48% in water was stirredand heated for 48 hours at 80° C. The reaction mixture was evaporatedand the residue was suspended in 2-propanol. The product was filteredoff and dried, yielding 18.5 parts (95.7%) of2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-1-[(4-fluorophenyl)methyl]-1H-benzimidazol-5-oltrihydrobromide monohydrate; mp. +250° C. (intermediate 140).

EXAMPLE XXV

To a stirred and cooled (below 10° C.) mixture of 5.04 parts of carbondisulfide, 2.06 parts of N,N'-methanetetraylbis[cyclohexanamine]and 45parts of tetrahydrofuran was added dropwise a solution of 3.7 parts ofN-[1-(2-aminoethyl)-4-piperidinyl]-1-(4-fluorophenylmethyl)-1H-benzimidazol-2-aminein tetrahydrofuran. Upon completion, stirring was continued overnightwhile the mixture was allowed to reach room temperature. The reactionmixture gas evaporated. The residue was purified bycolumn-chromatography over silica gel using a mixture oftrichloromethane and methanol (98:2 by volume) as eluent. The purefractions were collected and the eluent was evaporated, yielding 4 parts(100%) of1-(4-fluorophenylmethyl)-N-[1-(2-isothiocyanatoethyl)-4-piperidinyl]1H-benzimidazol-2-amineas a residue (intermediate 141).

In a similar manner there were also prepared:

1-(2-furanylmethyl)-N-[1-(2-isothiocyanatoethyl)-4-piperidinyl]-1H-benzimidazol-2-amine(intermediate 142);

1-[(4-fluorophenyl)methyl]-N-[1-(2-isothiocyanatoethyl)-4-piperidinyl]-1H-imidazo[4,5-b]pyridin-2-amineas a residue (intermediate 143);

N-[1-(2-isothiocyanatoethyl)-4-piperidinyl]-3-(2-pyridinylmethyl)-31H-imidazo[4,5-b]pyridin-2-amine(intermediate 144); and

3-[(4-fluorophenyl)methyl]-N-[1-(2-isothiocyanatoethyl)-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-amineas a residue (intermediate 145).

B. Preparation of Final Compounds EXAMPLE XXVI 1st. Method

A mixture of 1.14 parts of 2-chloropyrimidine, 3.7 parts ofN-[1-(2-aminoethyl)-4-piperidinyl]-1-(4-fluorophenylmethyl)-1H-benzimidazol-2-amine,1.06 parts of sodium carbonate, 0.1 parts of potassium iodide and 135parts of N,N-dimethylformamide was stirred and heated overnight at 70°C. The reaction mixture was poured onto water and the product wasextracted with 4-methyl-2-pentanone. The extract was dried, filtered andevaporated. The residue was purified by column-chromatography oversilica gel using a mixture of trichloromethane and methanol (96:4 byvolume), saturated with ammonia, as eluent. The pure fractions werecollected and tbe eluent was evaporated. The residue was crystallizedfrom acetonitrile, yielding 1.5 parts (34%) of1-[(4-fluorophenyl)methyl]-N-[1-[2-[(2-pyrimidinyl)amino]ethyl]-4piperidinyl]-1H-benzimidazol-2-amine; mp. 168.4° C. (compound 1).

2nd. Method

A mixture of 34.5 parts of 2-chloropyrimidine, 110 parts ofN-[1-(2-aminoethyl)-4-piperidinyl]-1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-amine,25 parts of sodium hydrogen carbonate and 1200 parts of ethanol wasstirred and refluxed overnight. The reaction mixture was cooled andfiltered over Hyflo. The filtrate was evaporated. The residue waspurified by HPLC over silica gel using a mixture of trichloromethane andmethanol (95:5 by volume) saturated with ammonia, as eluent. The purefractions were collected and the eluent was evaporated. The residue wascrystallized from acetonitrile, yielding 82 parts (61%) of1-[(4-fluorophenyl)methyl]-N-[1-[2-[(2-pyrimidinyl)amino]-ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine;mp. 168.4° C. (compound 1).

Following the procedure described in the first method and usingequivalent amounts of the appropriate starting materials there were alsoprepared:

    __________________________________________________________________________     ##STR37##                                                                    Comp.                                   Base or                                                                            mp.                              No. L                   R.sup.1   R.sup.n                                                                             salt in °C.                    __________________________________________________________________________    2   4-[(2-pyrimidinyl)NH]butyl                                                                        4-FC.sub.6 H.sub.4 CH.sub.2                                                             H     base 150.0                            3   2-[(3-NO.sub.22-pyridinyl)NH]ethyl                                                                4-FC.sub.6 H.sub.4 CH.sub.2                                                             H     base 148.1                            4   3-[(2-pyrimidinyl)NH]propyl                                                                       4-FC.sub.6 H.sub.4 CH.sub.2                                                             H     base 143.8                            5   2-[(6-Cl4-pyrimidinyl)NH]ethyl                                                                    4-FC.sub.6 H.sub.4 CH.sub.2                                                             H     2HCl 277.9                            6   1-(2-pyrimidinyl)-4-piperidinyl                                                                   4-FC.sub.6 H.sub.4 CH.sub.2                                                             H     base 158.7                            7   2-[(2-pyrimidinyl)NH]propyl                                                                       4-FC.sub.6 H.sub.4 CH.sub.2                                                             H     base 160.8                            8   2-[(phenylmethyl)(2-pyrimidinyl)NH]ethyl                                                          4-FC.sub.6 H.sub.4 CH.sub.2                                                             H     base 148.7                            9   2-(3-NO.sub.22-pyridinyl)NH]propyl                                                                4-FC.sub.6 H.sub. 4 CH.sub.2                                                            H     2HCl.                                                                              229.3                                                                    11/2H.sub.2 O                         10  2-[CH.sub.3 (2-pyrimidinyl)N]ethyl                                                                4-FC.sub.6 H.sub.4 CH.sub.2                                                             H     base 167.2                            11  1-(3-NO.sub.22-pyridinyl)-4-piperidinyl                                                           4-FC.sub.6 H.sub.4 CH.sub.2                                                             H     2H.sub.2 O                                                                         108-123                          12  1-(2-pyrimidinyl)-3-piperidinyl                                                                   4-FC.sub.6 H.sub.4 CH.sub.2                                                             H     base 177.1                            13  2-[(5-NO.sub.22-pyridinyl)NH]ethyl                                                                4-FC.sub.6 H.sub.4 CH.sub.2                                                             H     base 175.7                            14  2-[(4-NO.sub.2,  .sub.--Noxide-3-pyridinyl]NH]ethyl                                               4-FC.sub.6 H.sub.4 CH.sub.2                                                             H     base 199.0                            15  2-[(2-pyrimidinyl)NH]ethyl                                                                        (2-pyridinyl)CH.sub.2                                                                   H     base 150.8                            16  2-[(2-pyrimidinyl)NH]ethyl                                                                        4-FC.sub.6 H.sub.4 CH.sub.2                                                             2(and 3)F                                                                           base 180.9                            17  2-[(2-pyrimidinyl)NH]ethyl                                                                        (3-pyridinyl)CH.sub.2                                                                   H     base 218.9                            18  2-[(2-pyrimidinyl)NH]ethyl                                                                        (2-pyrazinyl)CH.sub.2                                                                   H     base 185.8                            19  2-[(2-pyrimidinyl)NH]ethyl                                                                        (2-thienyl)CH.sub.2                                                                     H     base 181.5                            20  2-[(2-pyrimidinyl)NH]ethyl                                                                        (3-furanyl)CH.sub.2                                                                     H     base 213.3                            21  2-[(2-pyrimidinyl)NH]ethyl                                                                        (5-CH.sub.32-furanyl)                                                                   H     base 143.7                                                    CH.sub.2                                              22  5-[(2-pyrimidinyl)NH]pentyl                                                                       4-FC.sub.6 H.sub.4 CH.sub.2                                                             H     base 136.5                            __________________________________________________________________________

The following compounds were also prepared following the proceduredescribed in the first method:

3-[(4-fluorophenyl)methyl]-N-[1-[2-[(2-pyridinyl)amino]ethyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-amine;mp. 181.8° C. (compound 23);

2-[[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin2-yl]amino]-1-piperidinyl]ethyl]amino]-3-pyridinecarboxamide;mp. 205.4° C. (compound 24);

1-[(4-fluorophenyl)methyl]-N-[1-[2-[(2-pyrimidinyl)amino]ethyl]-4-piperidinyl]-1H-imidazo[4,5-b]pyridin-2-amine;mp. 165.6° C. (compound 25);

1-[(4-fluorophenyl)methyl]-N-[1-[2-(2-pyrimidinylamino]ethyl]-4-piperidinyl]-1H-imidazo[4,5-c]pyridin-2-amine;mp. 203.1° C. (compound 26);

3-(2-pyridinylmethyl)-N-[1-[2-(2-pyrimidinylamino)ethyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-amine(E)-2-butenedioate (2:3); mp. 181.2° C. (compound 27);

3-(2-furanylmethyl)-N-[1-[2-(2-4pyrimidinylamino)ethyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-amine;mp. 139.9° C. (compound 28);

3-[(4-fluorophenyl)methyl]-N-[1-[2-[(2-pyrimidinyl)amino]ethyl]-4piperidinyl]-3H-imidazo[4,5-c]pyridin-2-amine(E)-2-butenedioate (1:2); mp. 198.0° C. (compound 29);

N-[1-[3-[(5-chloro-2-pyridinyl)amino]propyl]-4-piperidinyl]-1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-aminetrihydrochloride monohydrate; mp. 196.5° C. (compound 30);

6-chloro-N⁴-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-4,5-pyrimidinediamine;mp. 216.7° C. (compound 31); and

8-chloro-N-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazolyl-2-amino]-1-piperidinyl]ethyl]-3-phthalazinamine2propanolate (1:1); mp. 139.7° C. (compound 32).

EXAMPLE XXVII

Following the procedure described in the first method of Example XXVIand using N,N-dimethylacetamide as solvent there were also prepared:

    __________________________________________________________________________     ##STR38##                                                                    Comp.                       Base or                                           No. Ar              R.sup.1 salt mp. in °C.                            __________________________________________________________________________    33  2-pyrazinyl     4-FC.sub.6 H.sub.4 CH.sub.2                                                           base 209.5                                        34  2,6-(NH.sub.2).sub.24-pyrimidinyl                                                             4-FC.sub.6 H.sub.4 CH.sub.2                                                           H.sub.2 O                                                                          133.3                                        35  2-NH.sub.2, 6-CH.sub.34-pyrimidinyl                                                           4-FC.sub.6 H.sub.4 CH.sub.2                                                           H.sub.2 O                                                                          124.7                                        36  3-NH.sub.2 CO2-pyridinyl                                                                      4-FC.sub.6 H.sub.4 CH.sub.2                                                           base 221.2                                        37  6-Cl3-pyridazinyl                                                                             4-FC.sub.6 H.sub.4 CH.sub.2                                                           base 196.8                                        38  4-quinolinyl    4-FC.sub.6 H.sub.4 CH.sub.2                                                           base 227.8                                        39  5-Br2-pyridinyl 4-FC.sub.6 H.sub.4 CH.sub.2                                                           base 183.3                                        40  3-Cl2-pyridinyl 4-FC.sub.6 H.sub.4 CH.sub.2                                                           base 124-145                                      41  3-CH.sub.32-quinoxalinyl                                                                      4-FC.sub.6 H.sub.4 CH.sub.2                                                           base 198.2                                        42  5-NH.sub.2 CO2-pyridinyl                                                                      4-FC.sub.6 H.sub.4 CH.sub.2                                                           base 268.2                                        43  2-pyrimidinyl   (2-furanyl)CH.sub.2                                                                   base 186.8                                        44  2-quinolinyl    4-FC.sub.6 H.sub.4 CH.sub.2                                                           base 145.2                                        45  3-Cl2-pyridinyl 4-FC.sub.6 H.sub.4 CH.sub.2                                                           3HCl --                                           46  3-NH.sub.2 CO2-pyridinyl                                                                      (2-furanyl)CH.sub.2                                                                   base 246.2                                        __________________________________________________________________________

    __________________________________________________________________________     ##STR39##                                                                                                                        base                                                                                 mp.                No.                                                                              L                 R  R.sup.1      R.sup.2                                                                          A           salt   °C.         __________________________________________________________________________    47 2-[(3-Cl2-pyridinyl)amino]ethyl                                                                 H  4-FC.sub.6 H.sub.4 CH.sub.2                                                                H  NCHCHCH     base   146.5              48 2-[(2-pyrimidinyl)amino]ethyl                                                                   H  5-CH.sub.34-imidazolyl-CH.sub.2                                                            H  CHCHCHCH    base   184.2              49 2-[(5-Br2-pyridinyl)amino]ethyl                                                                 H  C.sub.6 H.sub.5 CH.sub.2                                                                   H  CHCHCHCH    base   164.0              50 2-[(5-Br2-pyridinyl)amino]ethyl                                                                 H  CH.sub.3     H  CHCHCHCH    base   --                 51 2-[(5-Br2-pyridinyl)amino]ethyl                                                                 H  4-CH.sub.3C.sub.6 H.sub.4 CH.sub.2                                                         H  CHCHCHCH    base   --                 52 2-[(5-Br2-pyridinyl)amino]ethyl                                                                 H  4-CH.sub.3 OC.sub.6 H.sub.4 CH.sub.2                                                       H  CHCHCHCH    base   --                 53 2-[(5-Cl2-pyridinyl)amino]ethyl                                                                 H  4-FC.sub.6 H.sub.4 CH.sub.2                                                                H  CHCHCHCH    base   --                 54 4-[(5-Cl2-pyridinyl)amino]butyl                                                                 H  4-FC.sub.6 H.sub.4 CH.sub.2                                                                H  CHCHCHCH    base   --                 55 1-(5-Cl2-pyridinyl)-4-                                                                          H  4-FC.sub.6 H.sub.4 CH.sub.2                                                                H  CHCHCHCH    base   --                    piperidinyl                                                                56 2-[(5-Cl2-pyridinyl)methyl                                                                      H  4-FC.sub.6 H.sub.4 CH.sub.2                                                                H  CHCHCHCH    base   143.2                 amino]ethyl                                                                57 5-[(5-Cl2-pyridinyl)amino]pentyl                                                                H  4-FC.sub.6 H.sub.4 CH.sub.2                                                                H  CHCHCHCH    base   --                 58 2-[(5-Cl2-pyridinyl)amino]ethyl                                                                 H  4-FC.sub.6 H.sub.4 CH.sub.2                                                                CH.sub.3                                                                         CHCHCHCH    base   -- and             59 2-[(2-pyrimidinyl)amino]ethyl                                                                   CH.sub.3                                                                         4-FC.sub.6 H.sub.4 CH.sub.2                                                                H  CHCHCHCH    (cis                                                                                 217.2ns)                                                               3 HCl                     __________________________________________________________________________

EXAMPLE XXVIII

A mixture of 3.7 parts ofN-[1-(2-aminoethyl)-4-piperidinyl]-1-(4-fluorophenylmethyl)-1H-benzimidazol-2-aine,1 part of N,N-diethylethanamine and 45 parts of tetrahydrofuran wasstirred at -20° C. and there was added dropwise a solution of 1.5 partsof 2,4-dichloropyrimidine in tetrahydrofuran at this temperature. Uponcompletion, the mixture was allowed to reach slowly room temperature andstirring was continued overnight at room temperature. The precipitatewas filtered off and the filtrate was evaporated. The residue waspurified by column-chromatography over silica gel using a mixture oftrichloromethane and methanol (90:10 by volume), saturated with ammonia,as eluent. The pure fractions were collected and the eluent wasevaporated. The residue was converted into the hydrochloride salt in2-propanol. The salt was filtered off and dried, yielding 1.7 parts ofN-[1-[2-[(2-chloro-4-pyrimidinyl)amino]ethyl]-4-piperidinyl]-1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-aminedihydrochloride monohydrate; mp. 287.4° C. (compound 60).

In a similar manner there were also prepared:

N-[1-[2-[(2-chloro-6-methyl-4-pyrimidinyl)amino]ethyl]-4-piperidinyl]-1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-amine;mp. 124.4° C. (compound 61); and

N-[1-[2-[(4-chloro-6-methyl-2-pyrimidinyl)amino]ethyl]-4-piperidinyl]-1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-amine;mp. 151.9° C. (compound 62).

EXAMPLE XXIX

A mixture of 3.4 parts of 6-chloro-3-nitro-2-pyridinamine, 7.4 parts ofN-[1-(2-aminoethyl)-4-piperidinyl]-1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-amine and 10 parts of 1-methyl-2-pyrrolidinone wasstirred and heated for 2 hours at 150° C. The reaction mixture wascooled and taken up in methanol saturated with ammonia. The whole wasevaporated and water was added to the residue. The product was extractedthree times with 4-methyl-2-pentanone. The combined extracts were dried,filtered and evaporated in vacuo. The residue was purified bycolumn-chromatography over silica gel using a mixture oftrichloromethane and methanol (95:5 by volume) as eluent. The purefractions were collected and the eluent was evaporated. The residue wascrystallized from 4-methyl-2-pentanone, yielding 5 parts (50%) of N⁶-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-amino]-1-piperidinyl]ethyl]-3-nitro-2,6-pyridinediamine;mp. 205.7° C. (compound 63).

EXAMPLE XXX

A mixture of 1.7 parts of 2-chloropyrimidine, 9.66 parts of2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-1-[(4-fluorophenyl)methyl]-1H-benzimidazol-5-oltrihydrobromide, 5 parts of sodium hydrogen carbonate and 80 parts ofethanol was stirred and refluxed overnight. The reaction mixture wasevaporated and the residue was taken up in trichloromethane. The organicphase was washed with water, dried, filtered and evaporated. The residuewas crystallized from a mixture of acetonitrile and methanol, yielding5.2 parts (83%) of1-[(4-fluorophenyl)methyl]-2-[[1-[2-(2-pyrimidinylamino)ethyl]-4-piperidinyl]amino]-1e,uns/H/-benzimidazol-5-ol; mp. 194.4° C. (compound 64).

In a similar manner there were also prepared:

1-(phenylmethyl)-N[1-[2-[(2-pyrimidinyl)amino]ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine;mp. 188.3° C. (compound 65);

1-methyl-N-[1-[2-[(2-pyrimidinyl)amino]ethyl]-4-piperidinyl]-1H-benzimidazol-2-aminehemihydrate; mp. 120.9° C. (compound 66);

1-[(4methylphenyl)methyl]-N-[1-[2-[(2-pyrimidinyl)amino]ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine;mp. 123.6° C. (compound 67);

1-[(4-chlorophenyl)methyl]-N-[1-[2-(2-pyrimidinylamino)ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine;mp. 137.8° C. (compound 68);

1-[(4-methoxyphenyl)methyl]-N-[1-[2-(2-pyrimidinylamino)ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine;mp. 160.4° C. (compound 69);

N-[1-[2-(2-pyrimidinylamino)ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine;mp. 208.6° C. (compound 70);

1-[(4-fluorophenyl)methyl]-5-methoxy-N-[1-[2-(2-pyrimidinylamino)ethyl]-4-piperidinyl]-1e,uns/H/-benzimidazol-2-amine; mp. 160.7° C. (compound 71);

N-[1-[2-(2-pyrimidinylamino)ethyl]-4-piperidinyl]-1-(4-thiazolylmethyl)-1H-benzimidazol2-amine(E)-2-butenedioate (1:2); mp. 173.9° C. (compound 72);

4-[[2-[[1-[2-(2-pyrimidinylamino)ethyl]-4-piperidinyl]amino]-1H-benzimidazol-1-yl]methyl]phenol;mp. 230.8 C. (compound 2-(2-pyrimidinylamino)]

1-[(4-fluorophenyl)methyl]-6methoxy-N[1[73ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine; mp. 200.1° C.(compound 74);

1-[(4-fluorophenyl)methyl]-N-methyl-N-[1-[2-(2-pyrimidinylamino)ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine;mp. 101.3° C. (compound 75); and

N-(phenylmethyl)-N-[1-[2-(2-pyrimidinylamino)ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine;mp. 207.1° C. (compound 76).

EXAMPLE XXXI

5.5 Parts of4-[1-(4-fluorophenylmethyl)-1H-benzimidazol-2-ylamino]-1-piperidineethanoland 135 parts of N,N-dimethylformamide were stirred at room temperatureand 0.75 parts of a sodium hydride dispersion 50% were added. Afterstirring for one hour at room temperature, 2.5 parts of2-chloroquinoline were added and the whole was stirred overnight at roomtemperature. The reaction mixture was poured onto water and the productwas extracted with 4-methyl-2-pentanone. The extract was dried, filteredand evaporated. The residue was crystallized from acetonitrile, yielding4.3 parts (58%) of1-[(4-fluorophenyl)methyl]-N-[1-[2-(2-quinolinyloxy)ethyl]-4-piperidinyl]1H-benzimidazol-2-amine;mp. 149.9° C. (compound 77)

In a similar manner there were also prepared:

N-[1-[2-[(5-bromo-2-pyridinyl)oxy]ethyl]-4-piperidinyl]-1-(2-furanylmethyl)-1H-benzimidazol-2-amine;mp. 160.5° C. (compound 78);

1-[(4-fluorophenyl)methyl]-N-[1-[2-[[2-(methylthio)-4-pyrimidinyl]oxy]ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine;mp. 120.6° C. (compound 79);

1-[(4-fluorophenyl)methyl]-N-[1-[2-[(3-methyl-2-quinoxalinyl)oxy]ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine;mp. 168.4° C. (compound 80);

1-[(4-fluorophenyl)methyl]-N-[1-[2-(2-pyrimidinyloxy)ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine;mp. 133.8° C. (compound 81);

N-[1-[2-[(5-bromo-2-pyridinyl)oxy]ethyl]-4-piperidinyl]-1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-amine;mp. 161.5° C. (compound 82);

1-(2-furanylmethyl)-N-[1-[2-(2-pyrimidinyloxy)ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine(E)-2-butenedioate (1:2); mp. 190.4° C. (compound 83); and

1-[(4-fluorophenyl)methyl]-N-[1-[2-(2-pyridinylmethoxy)ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine(E)-2-butenedioate (1:2); mp. 162° C. (compound 84).

EXAMPLE XXXII

A mixture of 2.7 parts of5-[(4-chlorophenyl)methyl]-2-(methylthio)-4(1H)-pyrimidinone and 3.67parts ofN-[1-(2-aminoethyl)-4-piperidinyl]-1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-amine was stirred and heated for 4 hours at 140° C. The reactionmixture was cooled and taken up in trichloromethane. The solution waspurified by column-chromatography over silica gel using a mixture oftrichloromethane and methanol (96:4 by volume), saturated with ammonia,as eluent. The pure fractions were collected and the eluent wasevaporated. The residue was suspended in 1,1'-oxybisethane, yielding 4.5parts (76.8%) of5-[(4-chlorophenyl)methyl]-2-[[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]amino]-4(1H)-pyrimidinonemonohydrate; mp. 150.6°-158.7° C. (compound 85).

Following the same procedure and using equivalent amounts of theappropriate starting materials there were also prepared:

2-[[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-amino]-1-piperidinyl]ethyl]amino]-6-propyl-4-pyrimidinol;mp. 164.8° C. (compound 86);

2-[[2-[[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-amino]-1-piperidinyl]ethyl]amino]-4(1H-pyrimidinone;mp. 150.4° C. (compound 87);

2-[[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-4(1H)-quinazolinone;mp. 264.2° C. (compound 88);

2-[[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]amino]-6-(phenylmethyl)-4(1H)-pyrimidinone;mp. 134.5° C. (compound 89); and

2-[[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-6-methyl-4(1H)-pyrimidinone;mp. 143.6° C. (compound 90).

EXAMPLE XXXIII

A mixture of 1.12 parts of 2-pyrimidinethiol, 4.6 parts ofN-[1-(2-chloroethyl)-4-piperidinyl]-1-(4-fluorophenylmethyl)-1H-benzimidazol-2-aminedihydrochloride, 4 parts of potassium carbonate and 80 parts of2-propanone was stirred for 3 days at room temperature. The reactionmixture was filtered and the filtrate was evaporated. The residue waspurified by column-chromatography over silica gel using a mixture oftrichloromethane and methanol (95:5 by volume) as eluent. The purefractions were collected and the eluent was evaporated. The residue wascrystallized from a mixture of 2-propanone and 2,2'oxybispropane,yielding 1.7 parts (35.8%) of 1-[(4-fluorophenyl)methyl]-N-[1-[2-(2-pyrimidinylthio) ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine; mp.146.1°-147.7° C. (compound 91).

In a similar manner there was also prepared:

2-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-amino]-1-piperidinyl]ethylthio]-4(1H)-quinazolinonemonohydrate; mp. 133.4° C. (compound 92).

EXAMPLE XXXIV

To 1 part of a solution of 2 parts of thiophene in 40 parts of ethanolwere added 8 parts of1-[(4-fluorophenyl)methyl]-N-[1-[2-[(3-nitro-2-pyridinyl)amino]ethyl]-4-piperidinyl]-1H-benzimidazol-2-amineand 200 parts of methanol. The whole was hydrogenated at normal pressureand at room temperature with 2 parts of platinum-on-charcoal catalyst5%. After the calculated amount of hydrogen was taken up, the catalystwas filtered off and the filtrate was evaporated. The residue waspurified by column-chromatography over silica gel using a mixture oftrichloromethane and methanol (90:10 by volume) as eluent. The purefractions were collected and the eluent was evaporated. The residue wasconverted into the hydrochloride salt in acetonitrile and 2-propanol.The salt was filtered off and heated in ethanol. After stirring for awhile, the whole was cooled. The product was filtered off and dried,yielding 3.4 parts of N² -[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-2,3-pyridinediaminetrihydrochloride; mp. 256.5° C. (compound 93).

EXAMPLE XXXV

A mixture of 3.2 parts ofN-[1-[2-[(2-chloro-4-pyrimidinyl)amino]ethyl]-4-piperidinyl]-1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-aminedihydrochloride, 3 parts of calcium oxide and 120 parts of methanol washydrogenated at normal pressure and at room temperature with 2 parts ofpalladium-on-charcoal catalyst 20%. After the calculated amount ofhydrogen was taken up, the catalyst was filtered off and the filtratewas evaporated. The residue was crystallized from a mixture ofacetonitrile and 2,2'-oxybispropane. The product was filtered off anddried, yielding 1.1 parts of1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-pyrimidinylamino)ethyl]-4-piperidinyl]-1H-benzimidazol-2-aminehemihydrate; mp. 133.9° C. (compound 94).

In a similar manner there were also prepared:

N-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-1-phthalazinamine;mp. 178.1° C. (compound 95);

N⁴-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-4,5-pyrimidinediamine;mp. 207.7° C. (compound 96); and

N-[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-1'-(2-pyridinyl)-[1,4'-bipiperidin]-4-amine(E)-2-butenedioate (2:3) monohydrate; mp. 226.1° C. (compound 97).

EXAMPLE XXXVI

A mixture of 6 parts ofN-[1-[2-[(6-chloro-4-pyrimidinyl)amino]ethyl]-4-piperidinyl]-1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-amine,2.5 parts of a sodium methoxide solution 30% and 40 parts of methanolwas stirred and refluxed overnight. The reaction mixture was evaporatedand water was added to the residue. The product was extracted with4-methyl-2-pentanone. The extract was dried, filtered and evaporated.The residue was purified by column-chromatography over silica gel usinga mixture of trichloromethane and methanol (90:10 by volume) as eluent.The pure fractions were collected and the eluent was evaporated. Theresidue was crystallized from acetonitrile, yielding 1.4 parts of1-[(4-fluorophenyl)methyl]-N-[1-[2-[(6-methoxy-4-pyrimidinyl)amino]-ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine;mp. 145.8° C. (compound 98).

EXAMPLE XXXVII

A mixture of 4.5 parts of1-[(4-fluorophenyl)methyl]-N-[1-[2-[(2-pyrimidinyl)amino]ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine,15 parts of acetic acid anhydride and 140 parts of acetic acid wasstirred and refluxed overnight. The reaction mixture was evaporated. Theresidue was taken up in water and the whole was alkalized with ammoniumhydroxide. The product was extracted with dichloromethane. The extractwas dried, filtered and evaporated. The residue was purified by HPLCover silica gel using a mixture of methylbenzene and ethanol (90:10 byvolume) as eluent. The second fraction was collected and the eluent wasevaporated. The residue was converted into the (E)-2-butenedioate saltin methanol. The salt is filtered off and dried, yielding 1.2 parts(16.5%) ofN-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-N-(2-pyrimidinyl)acetamide(E)-2-butenedioate (1:2); mp. 191.1° C. (compound 99).

EXAMPLE XXXVIII

To a stirred and cooled (0°-10° C.) mixture of 4.45 parts of1-[(4-fluorophenyl)methyl]-N-[1-[2-[(2-pyrimidinyl)amino]ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine,1.5 parts of N,N-diethylethanamine and 45 parts of tetrahydrofuran wasadded dropwise a solution of 1.4 parts of benzoyl chloride in 45 partsof tetrahydrofuran. Upon completion, stirring was continued overnight atroom temperature. The reaction mixture was evaporated. The residue waspurified by column-chromatography over silica gel using a mixture oftrichloromethane and methanol (90:10 by volume) as eluent. The purefractions were collected and the eluent was evaporated. The residue wasconverted into the (E)-2-butenedioate salt in ethanol. The salt wasfiltered off and dried, yielding 4.9 parts ofN-[2-[4-[[1-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-amino]-1-piperidinyl]ethyl]-N-(2-pyrimidinyl)benzamide(E)-2-butenedioate (1:2); mp. 201.8° C. (compound 100).

EXAMPLE IXL

A mixture of 1.27 parts of 2ethenylpyrazine, 6.48 parts of 1-[(4fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-amine, 0.3parts of acetic acid and 40 parts of methanol was stirred and refluxedfor 48 hours. The solvent was evaporated. The residue was purified bycolumn-chromatography over silica gel using a mixture oftrichloromethane and methanol (88:12 by volume) as eluent. The purefractions were collected and the eluent was evaporated. The residue waswashed with 2,2'-oxybispropane and crystallized from 27 parts ofmethylbenzene, yielding 2.4 parts of1-)4-fluorophenylmethyl)-N-[1-[2-(2-pyrazinyl)ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine;mp. 165.3° C. (compound 101).

EXAMPLE XL

A mixture of 1 part of 3-pyridinemethanamine, 3.9 parts of1-(4-fluorophenylmethyl)-N-[1-(2-isothiocyanatoethyl)-4-piperidinyl]-1H-benzimidazol-2-amineand 45 parts of tetrahydrofuran was stirred for 4 hours at roomtemperature. The reaction mixture was evaporated in vacuo. The residuewas purified by column-chroratography over silica gel using a mixture oftrichloromethane and methanol (94:6 by volume) as eluent. The purefractions were collected and the eluent was evaporated. The residue wascrystallized from a mixture of 2-propanone and 2,2'-oxybispropane,yielding 3.4 parts (65.7%) ofN-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-N'-(3-pyridinylmethyl)thiourea;mp. 147.2° C. (compound 102).

In a similar manner there were also prepared:

N-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-N'-(2-pyridinylmethyl)thiourea;mp. 182° C. (compound 103);

N-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-N'-(3-pyridinyl)thiourea;mp. 113.5°-117.7° C. (compound 104);

N-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-N'-(2-pyridinyl)thiourea;mp. 192.6° C. (compound 105);

N-(4-amino-3-pyridinyl)-N'-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]thiourea;(compound 106);

N-(3-amino-2-pyridinyl)-N'-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]thiourea;(compound 107);

N-(4-amino-3-pyridinyl)-N'-[2-[4-[[1-(2-furanylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]thiourea;(compound 108);

N-(4-amino-3-pyridinyl)-N'-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]thiourea(compound 109);

N-(4-amino-3-pyridinyl)-N'-[2-[4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]thiourea(compound 110); and

N-(4-amino-3-pyridinyl)-N'-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]thiourea(compound 111).

EXAMPLE XLI

To a stirred mixture of 1.7 parts of 2-quinolinecarboxylic acid, 2.02parts of N,N-diethylethanamine and 195 parts of dichloromethane wereadded 2.55 parts of 2-chloro-1-methylpyrimidinium iodide and stirringwas continued for 15 minutes at room temperature. Then there was added amixture of 4.4 parts of4-[1-(4-fluoro-phenylmethyl)-1H-benzimidazol-2-ylamino]-1-piperidineethanoland 2.02 parts of N,N-diethylethanamine in 130 parts of dichloromethaneand the whole was stirred for one hour at room temperature. The reactionmixture was washed with water, dried, filtered and evaporated. Theresidue was purified by column-chromatography over silica gel using amixture of trichloromethane and methanol (95:5 by volume) as eluent.Thepure fractions were collected and the eluent was evaporated. The residuewas converted into the (E)-2-butenedioate salt in 2-propanone. The saltwas filtered off and dried, yielding 0.7 parts (9.5%) of[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]1-piperidinyl]-ethyl]-2-quinolinecarboxylate (E)-2-butenedioate (1:2);mp. 197.8° C. (compound 112).

EXAMPLE XLII

To a stirred mixture of 2.1 parts of 3amino-2-pyrazirecarboxylic acid,2.8 parts of N,N-dibutylbutanamine and 195 parts of dichloromethane wereadded 3.83 parts of 2-chloro-1-methylpyridinium iodide. After stirringfor 15 minutes at room temperature, 5.5 parts ofN-[1-(2-aminoethyl)-4-piperidinyl]-1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-aminewere added and stirring was continued for one hour. The reaction mixturewas washed with water, dried, filtered and evaporated. The residue wasstirred in 2,2'-oxybispropane. The latter was decanted and the residuewas purified by column-chromatography over silica gel using a mixture oftrichloromethane and methanol (96:4 by volume) as eluent. The purefractions were collected and the eluent was evaporated. The residue wascrystallized from 1,1'-oxybisethane, yielding 2.8 parts (38%) of3-amino-N-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-2-pyrazinecarboxamide;mp. 156.9° C. (compound 113).

In a similar manner there were also prepared:

N-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-2-quinolinecarboxamide(E)-2-butenedioate (1:2); mp. 243.6° C. (compound 114);

2-chloro-N-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-3-pyridinecarboxamide(E)-2-butenedioate (1:2) hemihydrate; mp. 211.7° C. (compound 115); and

6-chloro-N-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-3-pyridinecarboxamide(E)-2-butenedioate (1:2); mp. 232.7° C. (compound 116).

EXAMPLE XLIII

A mixture of 2.2 parts of 3-bromo-1-propanamine hydrobromide, 4.1 partsof 1-[(4-fluorophenyl)methyl-]-N[1-(2-isothiocyanatoethyl)-4-piperidinyl]-1H-benzimidazol-2-amine, 2.2parts of sodium carbonate and 135 parts of tetrahydrofuran was stirredovernight at room temperature. The reaction mixture was further stirredand refluxed for 3 hours. The mixture was filtered and the filtrate wasevaporated. The residue was purified by column-chromatography oversilica gel using a mixture of trichloromethane and methanol (95:5 byvolume), saturated with ammonia, as eluent. The pure fractions werecollected and the eluent was evaporated. The residue was crystallizedfrom acetonitrile, yielding 2.5 parts of 1-[(4-fluorophenyl)methyl]-N-[1-[2-[(5,6-dihydro-4H-1,3thiazin-2-yl)amino]-ethyl]-4-piperidinyl]-1H-benzimidazol-2-aminemonohydrate; mp. 121.4° C. (compound 117).

What is claimed is:
 1. A chemical compound having the formula ##STR40##a pharmaceutically acceptable acid addition salt or a stereochemicallyisomeric for thereof, wherein:A' is--CH═N--CH═CH--(c) --CH═CH--N═CH--(d)--CH═CH--CH═N--(e), said N being attached to the carbon atom in4-position of the imidazole ring; R is a member selected from the groupconsisting of hydrogen and lower alkyl; R¹ is a member selected from thegroup consisting of hydrogen, C₁ -C₁₀ alkyl, C₃ -C₆ cycloaklyl, Ar¹ andlower alkyl substituted with one or two Ar¹ radicals provided R¹ is nothydrogen when A' is (e); R² is a member selected from the groupconsisting of hydrogen, lower alkyl, C₃ -C₆ cycloalkyl, (loweralkyl)--CO--and Ar² -lower alkyl; and L' is a radical of formula--AlK'--CN, --Alk--Y'H, ##STR41## or --Alk--Y--C(═X)--Z'H wherein n is Oor the integer 1 or 2;Alk is a lower alkanediyl radical having from 1 to6 carbond atoms; Alk' is a lower alkanediyl radical having from 1 to 5carbond atoms; Y is O, S, NR³ or a direct bond; Y' is O, S or NR³ ; X isO, S, CH--NO₂ or NR⁴ ; and Z' is O, S, or NR⁵ ; said R³ being hydrogen,lower alkyl, (Ar²) lower alkyl, 2-lower alkyloxy-1,2-dioxoethyl or aradical of formula --C(═X)--R⁶, R⁶ being hydrogen, lower alkyl, Ar², Ar²-lower alkyl, lower alkyloxy, Ar² -lower alkyloxy, mono-or di(loweralkyl)amino, Ar² -lower alkylamino or Ar² -lower alkyl(loweralkyl)amino; said R⁴ being hydrogen, lower alkyl, cyano, nitro, AR²-sulfonyl, lower alkylsulfonyl, lower alkylcarbonyl or AR² -carbonyl;said R⁵ being hydrogen or lower alkyl; and wherein Ar¹ is a memberselected from the group consisting of phenyl, phenyl substituted with upto three substituents each independently selected from the groupconsisting of halo, hydroxy, nitro, cyano, trifluoromethyl, lower alkyl,lower alkyloxy, lower alkylthio, mercapto, amino, mono- and di(loweralkyl)amino, carboxyl, lower alkyloxycarbonyl and (lower alkyl)--CO--;thienyl; halothienyl; furanyl, lower alkyl substituted furanyl;pyridinyl; pyrazinyl; thiazolyl and imidazolyl optionally substituted bylower alkyl; and wherein Ar² is a member selected from the groupconsisting of phenyl, phenyl substituted with up to three substituentseach independently selected from the group consisting of halo, hydroxy,nitro, cyano, trifluoromethyl, lower alkyl, lower alkyloxy, loweralkylthio, mcercapto, amino, mono- and di(lower alkyl) amino, carboxyl,lower alkyloxycarbonyl and (lower alkyl)-CO.
 2. An anti-allergiccomposition comprising and inert carrier and an anti-allergic effectiveamount of a compound having the formula ##STR42## a pharmaceuticallyacceptable acid addition salt or a stereochemically isomeric formthereof, wherein:A' is--CH═N--CH═CH--(c) --CH═CH--N═CH--(d)--CH═CH--CH═N--(e), said N being attached to the carbon atom in4-position of the imidazole ring; R is a member selected from the groupconsisting of hydrogen and lower alkyl; R¹ is a member selected from thegroup consisting of hydrogen, C₁ -C₁₀ alkyl, C₃ -C₆ cycloalkyl, Ar¹ andlower alkyl substituted with one or two Ar¹ radicals provided R¹ is nothydrogen when A' is (e); R² is a member selected from the groupconsisting of hydrogen, lower alkyl, C₃ -C₆ cycloalkyl, (loweralkyl)--CO--and Ar² -lower alkyl; and L' is a radical of formula--Alk'--CN, --Alk--Y'H, ##STR43## or --Alk--Y--C(═X)--Z'H wherein n is Oor the integer 1 or 2;Alk is a lower alkanediyl radical having from 1 to6 carbon atoms; Alk' is a lower alkanediyl radical having from 1 to 5carbon atoms; Y is O, S, Nr³ or a direct bond; Y' is O, S or NR³ ; X isO, S, CH--NO₂ or NR₄ ; and Z' is O, S, or NR⁵ ; said R₃ being hydrogen,lower alkyl, (Ar²)lower alkyl, 2-lower alkyloxy-1,2-dioxoethyl or aradical of formula --C(═X)--R⁶, R⁶ being hydrogen, lower alkyl, Ar², Ar²-lower alkyl, lower alkyloxy, Ar² -lower alkyloxy, mono- or di(loweralkyl)amino, Ar² -lower alkylamino or Ar² -lower alkyl(loweralkyl)amino; said R⁴ being hydrogen, lower alkyl, cyano, nitro, AR²-sulfonyl, lower alkylsulfonyl, lower alkylcarbonyl or AR² -carbonyl;said R⁵ being hydrogen and lower alkyl; and wherein Ar¹ is a memberselected from the group consisting of phenyl, phenyl substituted with upto three substituents each independently selected from the groupconsisting of halo, hydroxy, nitro, cyano, trifluoromethyl, lower alkyl,lower alkyloxy, lower alkylthio, mercapto, amino, mono- and di(loweralkyl)amino, carboxyl, lower alkyloxycarbonyl and (lower alkyl)--CO--;thienyl; halothienyl; furanyl; lower alkyl substituted furanyl;pyridinyl; pyrazinyl; thiazolyl and imidazolyl optionally substituted bylower alkyl; and wherein Ar² is a member selected from the groupconsisting of phenyl, phenyl substituted with up to three substituentseach independently selected from the group consisting of halo, hydroxy,nitro, cyano, trifluoromethyl, lower alkyl, lower alkyloxy, loweralkylthio, mcercapto, amino, mono- and di(lower alkyl) amino, carboxyl,lower alkyloxycarbonyl and (lower alkyl)--CO.
 3. A method of treatingallergic diseases in warm-blooded animals suffering from same whichmethod comprises the systemic administration to warm-blooded animals ofan effective anti-allergic amount of a compound having the formula##STR44## a pharmaceutically acceptable acid addition salt or astereochemically isomeric from thereof, wherein:A' is--CH═N--CH═CH--(c)--CH═CH--N═CH--(d) --CH═CH--CH═N--(e), said N being attached to thecarbon atom in 4-position of the imidazole ring; R is a member selectedfrom the group consisting of hydrogen and lower alkyl; R¹ is a memberselected from the group consisting of hydrogen C₁ -C₁₀ alkyl, C₃ -C₆cycloalkyl, Ar¹ and lower alkyl substituted with one or two Ar¹ radicalsprovided R¹ is not hydrogen when A' is (e); R² is a member selected fromthe group consisting of hydrogen, lower alkyl, C₃ -C₆ cycloalkyl, (loweralkyl)--CO--and Ar² -lower alkyl; and L' is a radical of formula--Alk'--CN, --Alk--Y'H, ##STR45## or --Alk--Y--C(═X)--Z'H wherein n is Oor the integer 1 or 2;Alk is a lower alkanediyl radical having from 1 to6 carbon atoms; Alk' is lower alkanediyl radical having from 1 to 5carbon atoms; Y is O, S, NR³ or a direct bond; Y' is O, S or NR³ ; X isO, S, CH--NO² or NR⁴ ; and Z' is O, S, or NR⁵ ; said R³ being hydrogen,lower alkyl, (Ar²)lower alkyl, 2-lower alkyloxy-1,2-dioxoethyl or aradical of formula --C(═X)--R⁶, R⁶ being hydrogen, lower alkyl, Ar², Ar²-lower alkyl, lower alkyloxy, Ar² -lower alkyloxy, mono- or di(loweralkyl)amino, Ar² -lower alkylamino or Ar² -lower alkyl(loweralkyl)amino; said R⁴ being hydrogen, lower alkyl, cyano, nitro, Ar²-sullfonyl, lower alkylsulfonyl, lower alkylcarbonyl or Ar² -carbonyl;said R⁵ being hydrogen and lower alkyl; and wherein Ar¹ is a memberselected from the group consisting of phenyl, phenyl substituted with upto three substituents each independently selected from the groupconsisting of halo, hydroxy, nitro, cyano, triflluoromethyl, loweralkyl, lower alkyloxy, lower alkylthio, mercapto, amino, mono- anddi(lower alkyl)amino, carboxyl, lower alkyloxycarbonyl and (loweralkyl)--CO--; thienyl; halothienyl; furanyl, lower alkyl substitutedfuranyl; pyridinyl; pyrazinyl; thiazolyl and imidazolyl optionallysubstituted by lower alkyl; and wherein Ar² is a member selected fromthe group consisting of phenyl, phenyl substituted with up to threesubstituents each independently selected from the group consisting ofhalo, hydroxy, nitro, cyano, trifluoromethyl, lower alkyl, loweralkyloxy, lower alkylthio, mcercapto, amino, mono- and di(lower alkyl)amino, carboxyl, lower alkyloxycarbonyl and (lower alkyl)--CO.